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Abstract: Objective. Clinical genetic testing is commercially available for rs61764370, an inherited 
variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with 
increased ovarian and breast cancer risk as well as with survival time. However, prior studies, 
emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated 
ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.  
Methods. Centralized genotyping and analysis was performed for 140,012 women enrolled in the 
Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast 
Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium 
of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7,904 BRCA2 mutation carriers).  
Results. We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94-1.04, p=0.74) or 
breast cancer (OR=0.98, 95% CI 0.94-1.01, p=0.19) and results were consistent among mutation 
carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97-1.23, p=0.14, breast cancer HR=1.04, 95% CI 
0.97-1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71-1.13, p=0.34, breast cancer HR=1.06, 
95% CI 0.94-1.19, p=0.35). Null results were also obtained for associations with overall survival 
following ovarian cancer (HR=0.94, 95% CI 0.83-1.07, p=0.38), breast cancer (HR=0.96, 95% CI 0.87-
1.06, p=0.38), and all other previously-reported associations.  
Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical 
outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility 
related to the prediction or management of these cancers. 
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Dear Editors, 
 
We are pleased to submit our manuscript “No Clinical Utility of KRAS 
Variant rs61764370 for Ovarian or Breast Cancer” for consideration for 
publication. This single nucleotide polymorphism (SNP) in the 3’ 
untranslated region of KRAS was initially reported in 2010 by Dr. Joanne 
Weidhaas et al. from Yale University to be associated with risk and 
outcome of ovarian or breast cancer.  Subsequent publications by her group 
have suggested relationships with risk and/or outcome of several other 
cancer types as well as endometriosis.   
 
Since 2010, Dr. Weidhaas’ company MiraDx has commercially marketed a 
test that utilizes this single SNP as a breast/ovarian cancer risk predictor.    
 
“If your patient tests positive for this mutation, this may impact how you 
follow her for cancer detection. Women who carry this mutation have > 
20% lifetime risk of developing breast cancer, and a 10% risk of developing 
an additional independent breast cancer after their first diagnosis. Thus, 
they may be considered for higher-level breast cancer screenings, such as 
MRIs, especially in the setting of dense breast tissue, as is common for 
KRAS-variant patients. Since women with this mutation are also at 
increased risk for ovarian cancer, consideration should be made for 
appropriate screening and management of their ovaries by a qualified 
physician, such as yourself or an OBGYN.” 
 
https://miradx.com/preovar-kras-variant-test-populations/ 
accessed 9/24/2014 
 
However, the publications by the Weidhaas group have been based on 
relatively small studies of a few hundred cases and controls, and, in many 
instances, subgroup analyses of much smaller numbers of subjects.  By 
way of example, one paper by the Weidhaas group in 2011 suggesting that 
the KRAS SNP was associated with triple negative breast cancer was based 
on the risk allele being present in eight of 24 breast cancer cases (Lancet 
Oncol. 2011;12:377-86).   
 
The KRAS SNP data we present in this paper is based on genotyping of 
140,012 women in the context of the Collaborative Oncological Gene-
Environment Study (COGS).  Our analysis was conducted by three well-
established international consortia, including the Ovarian Cancer 
Association Consortium (OCAC), the Breast Cancer Association 
Consortium (BCAC) and the Consortium of Modifiers of BRCA1 and 
BRCA2 (CIMBA).  These groups came together because of the need for 
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large studies and rigorous validation of ovarian and breast cancer risk variants with small effect sizes.  
Over the past five years, our consortia have used genome wide association studies to discover and 
validate more than 100 common variants that are associated with risk of these cancers at a genome-wide 
level of significance (p values < 5x10
-8
).  Here, we definitively show that this KRAS SNP is not associated 
with risk or outcome of ovarian or breast cancer; a forest plot of risk results is included below. 
 
Figure.  Associations between KRAS rs61764370 and breast and ovarian cancer (A) Risk: For BRCA1 and BRCA2 mutation 
carrier analyses, cases were affected BRCA1/BRCA2 mutation carriers and controls were unaffected BRCA1/BRCA2 mutation 
carriers, and relative risks were estimated by hazard ratios; for other analyses, relative risks are estimated by odds ratios; breast 
cancer risk analyses used BCAC data adjusted for study, age, and the seven European principal components; ovarian cancer 
analyses used OCAC data adjusted for study, age, and the five European principal components; BRCA1 and BRCA2 mutation 
carrier analyses used CIMBA data with age as follow-up time and stratified for country; (B) Outcome: Breast cancer analyses used 
BCAC data adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy and was 
stratified by study; ovarian cancer analyses used OCAC data adjusted for age at diagnosis (overall survival only), the five European 
principal components, histology (serous, mucinous, endometrioid, clear cell, and other epithelial), grade (low versus high), FIGO 
stage (I-IV), residual disease after debulking surgery (nil versus any), and stratified by study; analyses for BRCA1 and BRCA2 
mutation carriers used CIMBA data adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or 
chemotherapy, and preventive bilateral oophorectomy and was stratified by study; 95% CI, 95% confidence interval. 
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Although null results generally are less likely to be published (Science 2014,345:992), this paper warrants 
acceptance for two reasons.  First, the large size of this study refutes beyond any doubt the findings 
published previously.  Second, and more importantly, MiraDx’s test for the KRAS SNP continues to be 
marketed commercially.  Thus, it is in the public interest for these null data to be widely visible to the 
scientific and lay communities.  I will be presenting the ovarian cancer results at the 2015 SGO meeting. 
 
We believe that the marketing of this test is a disservice to women who are concerned about risk or 
prognosis of ovarian and breast cancer and that our work will ignite an important dialogue about 
marketing of predictive genetic tests.  Due to conflict of interest, we advise against the use of reviewers 
that are involved in MiraDx (i.e., Dr. Weidhaas and colleagues, see https://miradx.com/about/).   
 
Lastly, we realize that the numbers of authors, 366, is large.  Nonetheless, all of the authors of this paper 
fulfill the criteria for authorship, contributed to writing, and approved the submitted manuscript; other 
contributions are enumerated on the following pages.   
 
Thank you in advance for consideration of this timely and important translational paper. 
 
Sincerely, 
 
 
 
Andrew Berchuck, MD  
Professor and Director, Gynecologic Oncology 
Duke University Medical Center  
 
on behalf of  
the Ovarian Cancer Association Consortium (OCAC),  
the Breast Cancer Association Consortium (BCAC), and  
the Consortium of Modifiers of BRCA1/2 Penetrance (CIMBA). 
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Centre, Cancer Council Victoria, Melbourne, VIC, 
Australia; Department of Epidemiology and Preventive 
Medicine, Monash University, Melbourne, VIC, 
Australia 
contributed samples and data, 
edited manuscript 
Fiona.Bruinsma@canc
ervic.org.au 
45 1 
46 Joan  Brunet MD Genetic Counseling Unit, Hereditary Cancer Program, 
IDIBGI-Catalan Institute of Oncology, Girona, Spain 
contributed samples and data, 
edited manuscript 
jbrunet@iconcologia.n
et 
46 1 
47 Thomas  Brüning MD Institute for Prevention and Occupational Medicine of 
the German Social Accident Insurance, Institute of the 
Ruhr-Universität Bochum (IPA), Bochum, Germany 
contributed samples and data, 
edited manuscript 
bruening@ipa-dguv.de 47 1 
48 Agnieszka  Budzilowska MsC Department of Pathology and Laboratory Diagnostics 
the Maria Sklodowska-Curie Memorial Cancer Center 
and Institute of Oncology, Warsaw, Poland  
contributed samples and data, 
edited manuscript 
agnieszka.budzilowska
@coi.pl 
48 1 
49 Clareann H Bunker PhD Department of Epidemiology, University of Pittsburgh 
Graduate School of Public Health, Pittsburgh, PA, USA  
contributed samples and data, 
edited manuscript 
bunkerc@pitt.edu 49 1 
50 Barbara  Burwinkel PhD Department of Obstetrics and Gynecology, University 
of Heidelberg, Heidelberg, Germany; Molecular 
Epidemiology Group, German Cancer Research 
Center (DKFZ), Heidelberg, Germany 
contributed samples and data, 
edited manuscript 
Barbara.Burwinkel@m
ed.uni-heidelberg.de 
51 1 
51 Ralf  Butzow PhD Department of Pathology, Helsinki University Central 
Hospital, Helsinki, Finland; Department of Obstetrics 
and Gynecology, Helsinki University Central Hospital, 
University of Helsinki, Helsinki, Finland 
contributed samples and data, 
edited manuscript 
ralf.butzow@hus.fi   52 4 
52 Saundra S Buys MD Department of Oncological Sciences, Huntsman 
Cancer Institute, University of Utah School of 
Medicine, Salt Lake City, UT, USA 
contributed samples and data, 
edited manuscript 
saundra.buys@hci.uta
h.edu 
53 1 
53 Maria A Caligo PhD Section of Genetic Oncology, Department of 
Laboratory Medicine, University Hospital of Pisa, 
University of Pisa, Pisa, Italy 
contributed samples and data, 
edited manuscript 
adelaide.caligo@do.un
ipi.it 
54 1 
54 Ian  Campbell PhD Cancer Genetics Laboratory, Research Division, Peter 
MacCallum Cancer Centre, Melbourne, Australia; Sir 
Peter MacCallum Department of Oncology, The 
University of Melbourne, Australia; Department of 
Pathology, University of Melbourne, Melbourne, 
Victoria, Australia 
contributed samples and data, 
edited manuscript 
ian.campbell@peterma
c.org 
55 1 
55 Jonathan  Carter MD Gynaecological Oncology, The Chris O’Brien 
Lifehouse and The University of Sydney, Sydney, 
Australia 
contributed samples and data, 
edited manuscript 
j.carter@sydney.edu.a
u 
56 1 
56 Jenny  Chang-Claude PhD Division of Cancer Epidemiology, German Cancer 
Research Center (DKFZ), Heidelberg, Germany  
contributed samples and data, 
edited manuscript 
j.chang-claude@dkfz-
heidelberg.de 
57 1 
57 Stephen J Chanock MD, PhD Division of Cancer Epidemiology and Genetics, 
National Cancer Institute, Bethesda, MD, USA  
contributed samples and data, 
edited manuscript 
chanocks@mail.nih.go
v 
58 1 
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58 Kathleen  B M Claes PhD Center for Medical Genetics, Ghent University, Ghent, 
Belgium 
contributed samples and data, 
edited manuscript 
Kathleen.Claes@UGe
nt.be  
59 3 
59 J   Mar
griet  
Collée MD Department of Clinical Genetics, Erasmus University 
Medical Center, Rotterdam, The Netherlands  
contributed samples and data, 
edited manuscript 
j.collee@erasmusmc.n
l 
60 1 
60 Linda S Cook PhD Division of Epidemiology and Biostatistics, University 
of New Mexico, Albuquerque, NM, USA 
contributed samples and data, 
edited manuscript 
lcook@salud.unm.edu 61 1 
61 Fergus J Couch PhD Department of Health Sciences Research, Division of 
Epidemiology, Mayo Clinic, Rochester, MN, USA; 
Department of Laboratory Medicine and Pathology, 
Division of Experimental Pathology, Mayo Clinic, 
Rochester, MN, USA 
provided funding and 
contributed samples and data, 
edited manuscript 
Couch.fergus@mayo.e
du 
62 1 
62 Angela  Cox PhD Sheffield Cancer Research Centre, Department of 
Oncology, University of Sheffield, Sheffield, UK 
contributed samples and data, 
edited manuscript 
a.cox@sheffield.ac.uk 63 1 
63 Daniel   Cramer MD Obstetrics and Gynecology Epidemiology Center, 
Brigham and Women's Hospital and Harvard Medical 
School, Boston, MA, USA; Department of 
Epidemiology, Harvard School of Public Health, 
Boston, MA, USA 
contributed samples and data, 
edited manuscript 
dcramer@partners.org 64 1 
64 Simon  S Cross PhD Academic Unit of Pathology, Department of 
Neuroscience, University of Sheffield, Sheffield, UK  
contributed samples and data, 
edited manuscript 
s.s.cross@sheffield.ac.
uk 
65 1 
65 Julie M Cunningham PhD Department of Laboratory Medicine and Pathology, 
Division of Experimental Pathology, Mayo Clinic, 
Rochester, MN, USA 
performed genotyping and 
contributed samples and data, 
edited manuscript 
cunningham.julie@ma
yo.edu 
66 1 
66 Cezary  Cybulski PhD International Hereditary Cancer Center, Department of 
Genetics and Pathology, Pomeranian Medical 
Academy, Szczecin, Poland 
contributed samples and data, 
edited manuscript 
cezarycy@sci.pam.szc
zecin.pl 
67 1 
67 Kamila  Czene PhD Department of Medical Epidemiology and Biostatistics, 
Karolinska Institutet, Stockholm, Sweden  
contributed samples and data, 
edited manuscript 
kamila.czene@ki.se 68 1 
68 Francesca  Damiola PhD INSERM U1052, CNRS UMR5286, Université Lyon 1, 
Centre de Recherche en Cancérologie de Lyon, Lyon, 
France 
contributed samples and data, 
edited manuscript 
francesca.damiola@ly
on.unicancer.fr 
70 1 
69 Agnieszka  Dansonka-
Mieszkowska 
PhD Department of Pathology and Laboratory Diagnostics 
the Maria Sklodowska-Curie Memorial Cancer Center 
and Institute of Oncology, Warsaw, Poland  
contributed samples and data, 
edited manuscript 
agad@coi.waw.pl 71 1 
70 Hatef  Darabi PhD Department of Medical Epidemiology and Biostatistics, 
Karolinska Institutet, Stockholm, Sweden  
contributed samples and data, 
edited manuscript 
hatef.darabi@ki.se 72 1 
71 Miguel  de la Hoya PhD Molecular Oncology Laboratory, Hospital Clinico San 
Carlos, Madrid, Spain 
contributed samples and data, 
edited manuscript 
mdhoya@hotmail.com 73 1 
72 Anna  deFazio PhD Center for Cancer Research, University of Sydney at 
Westmead Millennium Institute, Sydney, Australia; 
Department of Gynaecological Oncology, Westmead 
Hospital, Sydney, Australia 
contributed samples and data, 
edited manuscript 
anna.defazio@sydney.
edu.au 
74 1 
73 Joseph   Dennis PhD Centre for Cancer Genetic Epidemiology, Department 
of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK 
contributed samples and data, 
edited manuscript 
jgd29@cam.ac.uk 75 1 
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74 Peter  Devilee PhD Department of Human Genetics, Leiden University 
Medical Center, Leiden, The Netherlands; Department 
of Pathology, Leiden University Medical Center, 
Leiden, The Netherlands 
contributed samples and data, 
edited manuscript 
p.devilee@lumc.nl 76 1 
75 Ed M Dicks PhD Centre for Cancer Genetic Epidemiology, Department 
of Oncology, University of Cambridge, Cambridge, UK  
contributed samples and data, 
edited manuscript 
emd43@medschl.cam.
ac.uk 
77 1 
76 Orland  Diez PhD Oncogenetics Laboratory, University Hospital Vall 
d’Hebron and Vall d’Hebron Institute of Oncology 
(VHIO), Barcelona, Spain 
contributed samples and data, 
edited manuscript 
odiez@vhebron.net 78 1 
77 Jennifer A Doherty PhD Section of Biostatistics and Epidemiology, The Geisel 
School of Medicine at Dartmouth, Lebanon, NH, USA  
contributed samples and data, 
edited manuscript 
jennifer.a.doherty@dar
tmouth.edu 
79 1 
78 Susan M Domchek MD Department of Medicine, Perelman School of Medicine 
at the University of Pennsylvania, Philadelphia, PA, 
USA; Basser Research Centre, Abramson Cancer 
Center, The University of Pennsylvania Perelman 
School of Medicine, Philadelphia, PA, USA 
contributed samples and data, 
edited manuscript 
Susan.Domchek@uph
s.upenn.edu 
80 1 
79 Cecilia M Dorfling MS Department of Genetics, University of Pretoria, 
Pretoria, South Africa 
contributed samples and data, 
edited manuscript 
Celmari.dorfling@up.a
c.za 
81 1 
80 Thilo  Dörk PhD Department of Obstetrics and Gynaecology, Hannover 
Medical School, Hannover, Germany 
contributed samples and data, 
edited manuscript 
doerk.thilo@mh-
hannover.de 
82 1 
81 Isabel  Dos Santos Silva PhD Non-Communicable Disease Epidemiology 
Department, London School of Hygiene and Tropical 
Medicine, London, UK 
contributed samples and data, 
edited manuscript 
isabel.silva@lshtm.ac.
uk 
83 1 
82 Andreas   du Bois MD Department of Gynecology and Gynecologic 
Oncology, Dr. Horst Schmidt Klinik Wiesbaden, 
Wiesbaden, Germany; Department of Gynecology and 
Gynecologic Oncology, Kliniken Essen-Mitte, Essen, 
Germany 
contributed samples and data, 
edited manuscript 
Prof.duBois@googlem
ail.com 
84 1 
83 Martine  Dumont PhD Centre Hospitalier Universitaire de Québec Research 
Center and Laval University, Quebec, Canada  
contributed samples and data, 
edited manuscript 
martine.dumont@crch
ul.ulaval.ca 
85 1 
84 Alison M Dunning PhD Centre for Cancer Genetic Epidemiology, Department 
of Oncology, University of Cambridge, Cambridge, UK  
contributed samples and data, 
edited manuscript 
amd24@medschl.cam.
ac.uk 
86 1 
85 Mercedes  Duran PhD Institute of Biology and Molecular Genetics, 
Universidad de Valladolid (IBGM-UVA), Valladolid, 
Spain 
contributed samples and data, 
edited manuscript 
merche@ibgm.uva.es 87 2 
86 Douglas F Easton PhD Centre for Cancer Genetic Epidemiology, Department 
of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK; Centre for Cancer 
Genetic Epidemiology, Department of Oncology, 
University of Cambridge, Cambridge, UK 
provided funding and 
contributed samples and data, 
edited manuscript 
dfe20@medschl.cam.a
c.uk 
88 1 
87 Diana  Eccles PhD Faculty of Medicine, University of Southampton, 
University Hospital Southampton, Southampton, UK  
contributed samples and data, 
edited manuscript 
d.m.eccles@soton.ac.
uk 
89 1 
88 Robert  Edwards MD Department of Obstetrics, Gynecology and 
Reproductive Sciences, Division of Gynecologic 
Oncology, University of Pittsburgh School of Medicine, 
Pittsburgh, PA, USA 
contributed samples and data, 
edited manuscript 
redwards@mail.magee
.edu 
90 1 
89 Hans  Ehrencrona MD Department of Clinical Genetics, Lund University, 
Lund, Sweden 
contributed samples and data, 
edited manuscript 
hans.ehrencrona@me
d.lu.se 
91 1 
10 
 
 
 
 
 
Order First M Last Degree Affiliation Contribution Email CoI Form 
# 
COI 
Batch 
90 Bent  Ejlertsen MD Department of Oncology, Rigshospitalet, Copenhagen 
University Hospital, Copenhagen, Denmark  
contributed samples and data, 
edited manuscript 
bent.ejlertsen@rh.regi
onh.dk 
92 1 
91 Arif  B Ekici PhD Institute of Human Genetics, Friedrich Alexander 
University Erlangen-Nuremberg, Erlangen, Germany 
contributed samples and data, 
edited manuscript 
arif.ekici@uk-
erlangen.de 
93 1 
92 Steve D Ellis MS Centre for Cancer Genetic Epidemiology, Department 
of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK 
contributed samples and data, 
edited manuscript 
sde26@medschl.cam.
ac.uk 
94 1 
93   EMBRACE  Centre for Cancer Genetic Epidemiology, Department 
of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK 
contributed samples and data, 
edited manuscript 
sde26@medschl.cam.
ac.uk 
95 1 
94 Christoph  Engel MD Institute for Medical Informatics, Statistics and 
Epidemiology, University of Leipzig, Leipzig, Germany  
contributed samples and data, 
edited manuscript 
christoph.engel@imise
.uni-leipzig.de 
96 1 
95 Mikael  Eriksson PhD Department of Medical Epidemiology and Biostatistics, 
Karolinska Institutet, Stockholm, Sweden  
contributed samples and data, 
edited manuscript 
mikael.eriksson@ki.se 97 1 
96 Peter A Fasching MD University Breast Center Franconia, Department of 
Gynecology and Obstetrics, University Hospital 
Erlangen, Erlangen, Germany; David Geffen School of 
Medicine, Department of Medicine Division of 
Hematology and Oncology, University of California at 
Los Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
peter.fasching@uk-
erlangen.de 
98 1 
97 Lidia  Feliubadalo PhD Molecular Diagnostic Unit, Hereditary Cancer 
Program, IDIBELL-Catalan Institute of Oncology, 
Barcelona, Spain 
contributed samples and data, 
edited manuscript 
lfeliubadalo@iconcolog
ia.net 
99 1 
98 Jonine  Figueroa PhD Division of Cancer Epidemiology and Genetics, 
National Cancer Institute, Bethesda, MD, USA  
contributed samples and data, 
edited manuscript 
figueroaj@mail.nih.gov 100 1 
99 Dieter  Flesch-Janys PhD Department of Cancer Epidemiology/Clinical Cancer 
Registry and Institute for Medical Biometrics and 
Epidemiology, University Clinic Hamburg-Eppendorf, 
Hamburg, Germany 
contributed samples and data, 
edited manuscript 
flesch@uke.de 69 1 
100 Olivia  Fletcher PhD Breakthrough Breast Cancer Research Centre, 
Division of Breast Cancer Research, The Institute of 
Cancer Research, London, UK 
contributed samples and data, 
edited manuscript 
Olivia.fletcher@icr.ac.u
k 
101 1 
101 Annette  Fontaine MD Clinical Cancer Genetics, City of Hope, Duarte, CA, 
USA; New Mexico Cancer Center, Albuquerque, NM, 
USA 
contributed samples and data, 
edited manuscript 
afontaine@nmohc.com 102 3 
102 Stefano  Fortuzzi PhD Fondazione Istituto FIRC di Oncologia Molecolare 
(IFOM), Milan, Italy; Cogentech Cancer Genetic Test 
Laboratory, Milan, Italy 
contributed samples and data, 
edited manuscript 
stefano.fortuzzi@ifom.
eu 
103 1 
103 Florentia  Fostira PhD Molecular Diagnostics Laboratory, Institute of Nuclear 
& Radiological Sciences & Technology, Energy & 
Safety, National Centre for Scientific Research 
Demokritos, Aghia Paraskevi Attikis, Athens, Greece  
contributed samples and data, 
edited manuscript 
florentia@rrp.demokrit
os.gr 
104 1 
104 Brooke L Fridley PhD Kansas IDeA Network of Biomedical Research 
Excellence Bioinformatics Core, The University of 
Kansas Cancer Center, Kansas City, KS, USA  
contributed samples and data, 
edited manuscript 
bfridley@kumc.edu 105 1 
105 Tara  Friebel MPH University of Pennsylvania, Philadelphia, PA, USA contributed samples and data, 
edited manuscript 
tfriebel@mail.med.upe
nn.edu 
106 1 
11 
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106 Eitan  Friedman MD The Susanne Levy Gertner Oncogenetics Unit, Sheba 
Medical Center, Tel-Hashomer, Israel; Institute of 
Oncology, Sheba Medical Center, Tel-Hashomer, 
Israel 
contributed samples and data, 
edited manuscript 
feitan@post.tau.ac.il 107 2 
107 Grace  Friel MS Department of Cancer Prevention and Control, 
Roswell Park Cancer Institute, Buffalo, NY, USA  
contributed samples and data, 
edited manuscript 
Grace.Friel@roswellpa
rk.org 
108 1 
108 Debra  Frost ONC Centre for Cancer Genetic Epidemiology, Department 
of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK 
contributed samples and data, 
edited manuscript 
djsf2@medschl.cam.a
c.uk 
109 1 
109 Judy  Garber MD Center for Cancer Genetics and Prevention, Dana-
Farber Cancer Institute, Boston, MA, USA  
contributed samples and data, 
edited manuscript 
Judy_Garber@dfci.har
vard.edu 
110 1 
110 Montserrat  García-Closas PhD Breakthrough Breast Cancer Research Centre, 
Division of Breast Cancer Research, The Institute of 
Cancer Research, London, UK 
contributed samples and data, 
edited manuscript 
Montse.GarciaClosas
@icr.ac.uk 
111 1 
111 Simon A Gayther PhD Department of Preventive Medicine, Keck School of 
Medicine, University of Southern California, Los 
Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
gayther@usc.edu 112 1 
112   GEMO Study Collaborators GEMO Study : National Cancer Genetics Network, 
UNICANCER Genetic Group, France 
contributed samples and data contributed samples 
and data, edited 
manuscript 
113 1 
113   GENICA 
Network 
 Dr. Margarete Fischer-Bosch-Institute of Clinical 
Pharmacology, Stuttgart, Germany; University of 
Tübingen, Tübingen, Germany; German Cancer 
Consortium (DKTK) and German Cancer Research 
Center (DKFZ), Heidelberg, Germany; Institute for 
Prevention and Occupational Medicine of the German 
Social Accident Insurance, Institute of the Ruhr-
Universität Bochum (IPA), Bochum, Germany; 
Department of Internal Medicine, Evangelische 
Kliniken Bonn gGmbH, Johanniter Krankenhaus, 
Bonn, Germany; Institute of Pathology, Medical 
Faculty of the University of Bonn, Bonn, Germany; 
Institute of Occupational Medicine and Maritime 
Medicine, University Medical Center Hamburg-
Eppendorf, Hamburg, Germany; Molecular Genetics of 
Breast Cancer, German Cancer Research Center 
(DKFZ), Heidelberg, Germany 
contributed samples and data, 
edited manuscript 
hiltrud.brauch@ikp-
stuttgart.de 
114 1 
114 Aleksandra  Gentry-Maharaj PhD Gynaecological Cancer Research Centre, Department 
of Women’s Cancer, Institute for Women's Health, 
UCL, London, UK 
contributed samples and data, 
edited manuscript 
a.gentry-
maharaj@ucl.ac.uk 
115 1 
115 Anne-Marie  Gerdes MD Department of Clinical Genetics, Rigshospitalet, 
Copenhagen University Hospital, Copenhagen, 
Denmark 
contributed samples and data, 
edited manuscript 
anne-
marie.gerdes@regionh
.dk 
116 1 
12 
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116 Graham G Giles PhD Centre for Epidemiology and Biostatistics, School of 
Population and Global Health, University of Melbourne, 
Melbourne, VIC, Australia; Cancer Epidemiology 
Centre, Cancer Council Victoria, Melbourne, VIC, 
Australia; Department of Epidemiology and Preventive 
Medicine, Monash University, Melbourne, VIC, 
Australia 
contributed samples and data, 
edited manuscript 
Graham.Giles@cancer
vic.org.au 
117 1 
117 Rosalind  Glasspool PhD Cancer Research UK Clinical Trials Unit, The Beatson 
West of Scotland Cancer Centre, Glasgow, UK  
contributed samples and data, 
edited manuscript 
ros.glasspool@ggc.sc
ot.nhs.uk 
118 1 
118 Gord  Glendon MS Ontario Cancer Genetics Network, Lunenfeld-
Tanenbaum Research Institute, Mount Sinai Hospital, 
Toronto, ON, Canada 
contributed samples and data, 
edited manuscript 
gglendon@uhnresearc
h.ca 
119 1 
119 Andrew K Godwin PhD Department of Pathology and Laboratory Medicine, 
University of Kansas Medical Center, Kansas City, KS, 
USA 
contributed samples and data, 
edited manuscript 
agodwin@kumc.edu 120 1 
120 Marc T Goodman PhD Samuel Oschin Comprehensive Cancer Institute, 
Cedars Sinai Medical Center, Los Angeles, CA, USA  
provided funding and 
contributed samples and data, 
edited manuscript 
marc.goodman@cshs.
org 
121 1 
121 Martin  Gore PhD Gynecological Oncology Unit, The Royal Marsden 
Hospital, London, UK 
contributed samples and data, 
edited manuscript 
Martin.Gore@rmh.nhs.
uk 
122 1 
122 Mark H Greene MD Clinical Genetics Branch, Division of Cancer 
Epidemiology and Genetics, National Cancer Institute, 
National Institutes of Health, Rockville, MD, USA  
contributed samples and data, 
edited manuscript 
greenem@mail.nih.gov 123 1 
123 Mervi    Grip PhD Department of Surgery, Oulu University Hospital, 
University of Oulu, Oulu, Finland 
contributed samples and data, 
edited manuscript 
mervi.grip@ppshp.fi 124 1 
124 Jacek  Gronwald MD Department of Genetics and Pathology, Pomeranian 
Medical University, Szczecin, Poland  
contributed samples and data, 
edited manuscript 
jgron@sci.pum.edu.pl 125 1 
125 Daphne   Gschwantler 
Kaulich 
MD Department of Obstetrics and Gynecology, 
Comprehensive Cancer Center, Medical University of 
Vienna, Vienna, Austria 
contributed samples and data, 
edited manuscript 
daphne.gschwantler-
kaulich@meduniwien.a
c.at 
126 1 
126 Pascal  Guénel PhD INSERM U1018, CESP (Center for Research in 
Epidemiology and Population Health), Environmental 
Epidemiology of Cancer, Villejuif, France; University 
Paris-Sud, UMRS 1018, Villejuif, France 
contributed samples and data, 
edited manuscript 
pascal.guenel@inserm
.fr 
127 1 
127 Starr R Guzman BS Department of Health Sciences Research, Division of 
Epidemiology, Mayo Clinic, Rochester, MN, USA  
contributed samples and data, 
edited manuscript 
guzman.starr@mayo.e
du 
128 1 
128 Lothar   Haeberle PhD University Breast Center Franconia, Department of 
Gynecology and Obstetrics, University Hospital 
Erlangen, Erlangen, Germany 
contributed samples and data, 
edited manuscript 
lothar.haeberle@uk-
erlangen.de 
129 1 
129 Christopher A Haiman PhD Department of Preventive Medicine, Keck School of 
Medicine, University of Southern California, Los 
Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
Christopher.Haiman@
med.usc.edu  
130 1 
130 Per  Hall PhD Department of Medical Epidemiology and Biostatistics, 
Karolinska Institutet, Stockholm, Sweden  
contributed samples and data, 
edited manuscript 
Per.Hall@ki.se  131 1 
131 Sandra L Halverson PhD Division of Epidemiology, Department of Medicine, 
Vanderbilt Epidemiology Center, Vanderbilt-Ingram 
Cancer Center, Vanderbilt University School of 
Medicine, Nashville, TN, USA 
contributed samples and data, 
edited manuscript 
sandra.l.deming@vand
erbilt.edu 
132 1 
13 
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132 Ute  Hamann PhD Molecular Genetics of Breast Cancer, German Cancer 
Research Center (DKFZ), Heidelberg, Germany  
contributed samples and data, 
edited manuscript 
u.hamann@dkfz-
heidelberg.de 
133 1 
133 Thomas  V O Hansen PhD Center for Genomic Medicine, Rigshospitalet, 
Copenhagen University Hospital, Copenhagen, 
Denmark 
contributed samples and data, 
edited manuscript 
tvoh@rh.dk 134 1 
134 Philipp  Harter MD Department of Gynecology and Gynecologic 
Oncology, Dr. Horst Schmidt Klinik Wiesbaden, 
Wiesbaden, Germany; Department of Gynecology and 
Gynecologic Oncology, Kliniken Essen-Mitte, Essen, 
Germany 
contributed samples and data, 
edited manuscript 
p.harter@gmx.de 135 1 
135 Jaana M Hartikainen PhD Imaging Center, Department of Clinical Pathology, 
Kuopio University Hospital, Kuopio, Finland; School of 
Medicine, Institute of Clinical Medicine, Pathology and 
Forensic Medicine, Biocenter Kuopio, Cancer Center 
of Eastern Finland, University of Eastern Finland, 
Kuopio, Finland 
contributed samples and data, 
edited manuscript 
jaana.hartikainen@uef.
fi 
136 1 
136 Sue   Healey BS Department of Genetics, QIMR Berghofer Medical 
Research Institute, Brisbane, Australia  
contributed samples and data, 
edited manuscript 
sueH@qimr.edu.au 137 1 
137   HEBON  The Hereditary Breast and Ovarian Cancer Research 
Group Netherlands (HEBON),Coordinating Center: 
Netherlands Cancer Institute, Amsterdam, The 
Netherlands  
contributed samples and data, 
edited manuscript 
m.hooning@erasmus
mc.nl 
138 1 
138 Alexander  Hein PhD University Hospital Erlangen, Department of 
Gynecology and Obstetrics, Friedrich-Alexander-
University Erlangen-Nuremberg, Comprehensive 
Cancer Center, Erlangen, Germany 
contributed samples and data, 
edited manuscript 
alexander.hein@uk-
erlangen.de 
139 1 
139 Florian  Heitz MD Department of Gynecology and Gynecologic 
Oncology, Dr. Horst Schmidt Klinik Wiesbaden, 
Wiesbaden, Germany; Department of Gynecology and 
Gynecologic Oncology, Kliniken Essen-Mitte, Essen, 
Germany 
contributed samples and data, 
edited manuscript 
florian.heitz@gmx.net 140 1 
140 Brian E Henderson MD Department of Preventive Medicine, Keck School of 
Medicine, University of Southern California, Los 
Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
Behender@usc.edu 141 1 
141 Josef  Herzog BS Clinical Cancer Genetics, City of Hope, Duarte, CA, 
USA 
contributed samples and data, 
edited manuscript 
jherzog@coh.org 142 1 
142 Michelle  A T Hildebrandt PhD Department of Epidemiology, The University of Texas 
MD Anderson Cancer Center, Houston, TX, USA  
contributed samples and data, 
edited manuscript 
mhildebr@mdanderso
n.org 
143 1 
143 Claus K Høgdall PhD Department of Gynecology, Rigshospitalet, University 
of Copenhagen, Copenhagen, Denmark 
contributed samples and data, 
edited manuscript 
hogdall@rh.dk 144 1 
144 Estrid  Høgdall PhD Virus, Lifestyle and Genes, Danish Cancer Society 
Research Center, Copenhagen, Denmark; Molecular 
Unit, Department of Pathology, Herlev Hospital, 
University of Copenhagen, Copenhagen, Denmark 
contributed samples and data, 
edited manuscript 
hogdall@dadlnet.dk 145 1 
145 Frans  B L Hogervorst PhD Netherlands Cancer Institute, Antoni van 
Leeuwenhoek Hospital, Amsterdam, The Netherlands  
contributed samples and data, 
edited manuscript 
f.hogervorst@nki.nl 146 1 
14 
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146 John L Hopper PhD Centre for Epidemiology and Biostatistics, School of 
Population and Global Health, University of Melbourne, 
Melbourne, VIC, Australia 
contributed samples and data, 
edited manuscript 
j.hopper@unimelb.edu
.au 
147 1 
147 Keith  Humphreys PhD Department of Medical Epidemiology and Biostatistics, 
Karolinska Institutet, Stockholm, Sweden  
contributed samples and data, 
edited manuscript 
Keith.Humphreys@ki.s
e 
148 1 
148 Tomasz  Huzarski PhD Department of Genetics and Pathology, Pomeranian 
Medical University, Szczecin, Poland  
contributed samples and data, 
edited manuscript 
huzarski@pum.edu.pl 149 1 
149 Evgeny N Imyanitov PhD N.N. Petrov Institute of Oncology, St. Petersburg, 
Russia 
contributed samples and data, 
edited manuscript 
evgeny@imyanitov.sp
b.ru 
150 1 
150 Claudine  Isaacs MD Lombardi Comprehensive Cancer Center, Georgetown 
University, Washington, DC, USA 
contributed samples and data, 
edited manuscript 
isaacsc@georgetown.
edu 
151 1 
151 Anna  Jakubowska PhD Department of Genetics and Pathology, Pomeranian 
Medical University, Szczecin, Poland  
contributed samples and data, 
edited manuscript 
aniaj@sci.pam.szczeci
n.pl 
152 1 
152 Ramunas  Janavicius MD Vilnius University Hospital Santariskiu Clinics, 
Hematology, Oncology and Transfusion Medicine 
Center, Department of Molecular and Regenerative 
Medicine; State Research Centre Institute for 
Innovative Medicine, Vilnius, Lithuania  
contributed samples and data, 
edited manuscript 
Ramunas.Janavicius@
santa.lt 
153 2 
153 Katarzyna  Jaworska PhD Department of Genetics and Pathology, Pomeranian 
Medical University, Szczecin, Poland; Postgraduate 
School of Molecular Medicine, Warsaw Medical 
University, Warsaw, Poland 
contributed samples and data, 
edited manuscript 
ka_jaworska@wp.pl 154 1 
154 Allan  Jensen PhD Virus, Lifestyle and Genes, Danish Cancer Society 
Research Center, Copenhagen, Denmark  
contributed samples and data, 
edited manuscript 
allan@cancer.dk 155 1 
155 Uffe Birk  Jensen PhD Department of Clinical Genetics, Aarhus University 
Hospital, Aarhus, Denmark 
contributed samples and data, 
edited manuscript 
uffejens@rm.dk 156 1 
156 Nichola   Johnson PhD Breakthrough Breast Cancer Research Centre, 
Division of Breast Cancer Research, The Institute of 
Cancer Research, London, UK 
contributed samples and data, 
edited manuscript 
Nichola.johnson@icr.a
c.uk 
157 1 
157 Arja  Jukkola-Vuorinen PhD Department of Oncology, Oulu University Hospital, 
University of Oulu, Oulu, Finland 
contributed samples and data, 
edited manuscript 
arja.jukkola-
vuorinen@ppshp.fi 
158 1 
158 Maria  Kabisch PhD Molecular Genetics of Breast Cancer, German Cancer 
Research Center (DKFZ), Heidelberg, Germany  
contributed samples and data, 
edited manuscript 
m.kabisch@dkfz.de 159 1 
159 Beth Y Karlan MD Women's Cancer Program, Samuel Oschin 
Comprehensive Cancer Institute, Cedars-Sinai Medical 
Center, Los Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
beth.karlan@cshs.org 160 1 
160 Vesa  Kataja PhD School of Medicine, Institute of Clinical Medicine, 
Pathology and Forensic Medicine, Biocenter Kuopio, 
Cancer Center of Eastern Finland, University of 
Eastern Finland, Kuopio, Finland; Jyväskylä Central 
Hospital, Jyväskylä, Finland 
contributed samples and data, 
edited manuscript 
vesa.kataja@ksshp.fi 161 1 
161 Noah  Kauff MD Clinical Genetics Research Laboratory, Memorial 
Sloan-Kettering Cancer Center, New York, NY, USA  
contributed samples and data, 
edited manuscript 
kauffn@mskcc.org 162 1 
162 KConFab  KConFab 
Investigators 
 kConFab: Kathleen Cuningham Consortium for 
Research into Familial Breast Cancer – Peter 
MacCallum Cancer Center, Melbourne, Australia 
contributed samples and data, 
edited manuscript 
heather.thorne@peter
mac.org 
163 1 
15 
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163 Linda E Kelemen PhD Department of Population Health Research, Alberta 
Health Services-Cancer Care, Calgary, Alberta, 
Canada; Department of Medical Genetics, University 
of Calgary, Calgary, Alberta, Canada; Department of 
Oncology, University of Calgary, Calgary, Alberta, 
Canada 
provided funding and 
contributed samples and data, 
edited manuscript 
LKelemen@post.harva
rd.edu 
164 1 
164 Michael J Kerin PhD School of Medicine, National University of Ireland, 
Galway, Ireland 
contributed samples and data, 
edited manuscript 
michael.kerin@nuigalw
ay.ie 
165 1 
165 Lambertus A Kiemeney PhD Department for Health Evidence, Radboud University 
Medical Centre, Nijmegen, Netherlands; Department of 
Urology, Radboud University Medical Centre, 
Nijmegen, Netherlands 
contributed samples and data, 
edited manuscript 
bart.kiemeney@radbo
udumc.nl 
166 1 
166 Susanne K Kjaer PhD Department of Gynecology, Rigshospitalet, University 
of Copenhagen, Copenhagen, Denmark; Virus, 
Lifestyle and Genes, Danish Cancer Society Research 
Center, Copenhagen, Denmark 
contributed samples and data, 
edited manuscript 
susanne@cancer.dk 167 1 
167 Julia A Knight PhD Division of Epidemiology, Dalla Lana School of Public 
Health, University of Toronto, Toronto, ON, Canada; 
Prosserman Centre for Health Research, Lunenfeld-
Tanenbaum Research Institute, Mount Sinai Hospital, 
Toronto, ON, Canada 
contributed samples and data, 
edited manuscript 
knight@lunenfeld.ca 168 1 
168 Jacoba P Knol-Bout MS Department of Epidemiology, Netherlands Cancer 
Institute, Amsterdam, The Netherlands  
contributed samples and data, 
edited manuscript 
cora.knol@gmail.com 169 1 
169 Irene  Konstantopoulou PhD Molecular Diagnostics Laboratory, Institute of Nuclear 
& Radiological Sciences & Technology, Energy & 
Safety, National Centre for Scientific Research 
Demokritos, Aghia Paraskevi Attikis, Athens, Greece  
contributed samples and data, 
edited manuscript 
reena@rrp.demokritos.
gr 
170 1 
170 Veli-Matti  Kosma PhD Imaging Center, Department of Clinical Pathology, 
Kuopio University Hospital, Kuopio, Finland; School of 
Medicine, Institute of Clinical Medicine, Pathology and 
Forensic Medicine, Biocenter Kuopio, Cancer Center 
of Eastern Finland, University of Eastern Finland, 
Kuopio, Finland 
contributed samples and data, 
edited manuscript 
veli-
matti.kosma@uef.fi 
171 1 
171 Camilla  Krakstad PhD Department of Gynecology and Obstetrics, Haukeland 
University Hospital, Bergen, Norway; Department of 
Clinical Science, University of Bergen, Bergen, Norway 
contributed samples and data, 
edited manuscript 
camilla.krakstad@med
.uib.no 
172 1 
172 Vessela  Kristensen PhD Department of Genetics, Institute for Cancer 
Research, Oslo University Hospital, Radiumhospitalet, 
Oslo, Norway; Faculty of Medicine (Faculty Division 
Ahus), Universitetet i Oslo, Norway 
contributed samples and data, 
edited manuscript 
Vessela.N.Kristensen
@rr-research.no 
173 2 
173 Karoline B Kuchenbaecker MS Centre for Cancer Genetic Epidemiology, Department 
of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK 
contributed samples and data, 
edited manuscript 
karoline@srl.cam.ac.u
k 
174 2 
174 Jolanta  Kupryjanczyk MD, PhD Department of Pathology and Laboratory Diagnostics 
the Maria Sklodowska-Curie Memorial Cancer Center 
and Institute of Oncology, Warsaw, Poland  
contributed samples and data, 
edited manuscript 
jkupry@coi.waw.pl 175 1 
16 
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175 Yael  Laitman MS The Susanne Levy Gertner Oncogenetics Unit, Sheba 
Medical Center, Tel-Hashomer, Israel; Institute of 
Oncology, Sheba Medical Center, Tel-Hashomer, 
Israel 
contributed samples and data, 
edited manuscript 
yael.laitman@gmail.co
m; 
yael.laitman@sheba.h
ealth.gov.il 
176 1 
176 Diether  Lambrechts PhD Laboratory for Translational Genetics, Department of 
Oncology, University of Leuven, Belgium; Vesalius 
Research Center (VRC), VIB, Leuven, Belgium 
contributed samples and data, 
edited manuscript 
Diether.Lambrechts@
med.kuleuven.be 
177 1 
177 Sandrina  Lambrechts PhD Division of Gynecologic Oncology , Department of 
Obstetrics and Gynaecology, University Hospitals 
Leuven, Leuven, Belgium; Leuven Cancer Institute, 
University Hospitals Leuven, Leuven, Belgium 
contributed samples and data, 
edited manuscript 
Sandrina.Lambrechts
@uzleuven.be 
178 2 
178 Melissa C Larson MS Department of Health Sciences Research, Division of 
Biomedical Statistics and Informatics, Mayo Clinic, 
Rochester, MN, USA 
contributed samples and data, 
edited manuscript 
melissa.larson@mayo.
edu 
179 1 
179 Adriana  Lasa PhD Genetic and Molecular Epidemiology Group, Human 
Cancer Genetics Program, Spanish National Cancer 
Research Centre (CNIO), Madrid, Spain  
contributed samples and data, 
edited manuscript 
ALasa@santpau.cat 180 4 
180 Pierre  Laurent-Puig PhD Université Paris Sorbonne Cité, UMR-S775 Inserm, 
Paris, France 
contributed samples and data, 
edited manuscript 
pierre.laurent-
puig@parisdescartes.fr 
181 1 
181 Conxi  Lazaro PhD Molecular Diagnostic Unit, Hereditary Cancer 
Program, IDIBELL-Catalan Institute of Oncology, 
Barcelona, Spain 
contributed samples and data, 
edited manuscript 
clazaro@iconcologia.n
et 
182 1 
182 Nhu  D Le PhD Cancer Control Research, BC Cancer Agency, 
Vancouver, BC, Canada 
contributed samples and data, 
edited manuscript 
nle@bccrc.ca 183 1 
183 Loic   Le Marchand PhD Cancer Epidemiology Program, University of Hawaii 
Cancer Center, Honolulu, HI, USA 
contributed samples and data, 
edited manuscript 
loic@crch.hawaii.edu 184 1 
184 Arto  Leminen PhD Department of Obstetrics and Gynecology, Helsinki 
University Central Hospital, University of Helsinki, 
Helsinki, Finland 
contributed samples and data, 
edited manuscript 
arto.leminen@hus.fi 185 1 
185 Jenny  Lester MPH Women's Cancer Program, Samuel Oschin 
Comprehensive Cancer Institute, Cedars-Sinai Medical 
Center, Los Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
jenny.lester@cshs.org 186 1 
186 Douglas A Levine MD Gynecology Service, Department of Surgery, Memorial 
Sloan-Kettering Cancer Center, New York, NY, USA  
contributed samples and data, 
edited manuscript 
levine2@MSKCC.OR
G 
187 1 
187 Jingmei  Li PhD Department of Medical Epidemiology and Biostatistics, 
Karolinska Institutet, Stockholm, Sweden  
contributed samples and data, 
edited manuscript 
jingmei@gmail.com 188 1 
188 Dong  Liang PhD College of Pharmacy and Health Sciences, Texas 
Southern University, Houston, TX, USA 
provided funding and 
contributed samples and data, 
edited manuscript 
Liang_DX@tsu.edu 189 1 
189 Annika  Lindblom PhD Department of Molecular Medicine and Surgery, 
Karolinska Institutet, Stockholm, Sweden  
contributed samples and data, 
edited manuscript 
Annika.Lindblom@ki.s
e 
190 4 
190 Noralane  Lindor MD Center for Individualized Medicine, Mayo Clinic, 
Scottsdale, AZ, USA 
contributed samples and data, 
edited manuscript 
lindor.noralane@mayo
.edu 
191 1 
191 Jolanta  Lissowska PhD Department of Cancer Epidemiology and Prevention, 
M. Sklodowska-Curie Memorial Cancer Center & 
Institute of Oncology, Warsaw, Poland  
contributed samples and data, 
edited manuscript 
lissowsj@coi.waw.pl 192 1 
17 
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192 Jirong  Long PhD Division of Epidemiology, Department of Medicine, 
Vanderbilt Epidemiology Center, Vanderbilt-Ingram 
Cancer Center, Vanderbilt University School of 
Medicine, Nashville, TN, USA 
contributed samples and data, 
edited manuscript 
jirong.long@vanderbilt.
edu 
194 1 
193 Karen H Lu MD Department of Gynecologic Oncology, University of 
Texas MD Anderson Cancer Center, Houston, TX, 
USA 
contributed samples and data, 
edited manuscript 
khlu@mdanderson.org
  
195 1 
194 Jan  Lubinski MD Department of Genetics and Pathology, Pomeranian 
Medical University, Szczecin, Poland  
contributed samples and data, 
edited manuscript 
lubinski@sci.pam.szcz
ecin.pl 
196 1 
195 Lene  Lundvall PhD Department of Gynecology, Rigshospitalet, University 
of Copenhagen, Copenhagen, Denmark 
contributed samples and data, 
edited manuscript 
lundvall@rh.dk 197 1 
196 Galina  Lurie PhD Cancer Epidemiology Program, University of Hawaii 
Cancer Center, Honolulu, HI, USA 
contributed samples and data, 
edited manuscript 
galina9@yahoo.com 198 1 
197 Phuong L Mai MD Clinical Genetics Branch, Division of Cancer 
Epidemiology and Genetics, National Cancer Institute, 
National Institutes of Health, Rockville, MD, USA  
contributed samples and data, 
edited manuscript 
maip@mail.nih.gov 199 1 
198 Arto  Mannermaa PhD Imaging Center, Department of Clinical Pathology, 
Kuopio University Hospital, Kuopio, Finland; School of 
Medicine, Institute of Clinical Medicine, Pathology and 
Forensic Medicine, Biocenter Kuopio, Cancer Center 
of Eastern Finland, University of Eastern Finland, 
Kuopio, Finland 
contributed samples and data, 
edited manuscript 
arto.mannermaa@uef.f
i 
200 1 
199 Sara  Margolin PhD Department of Oncology and Pathology, Karolinska 
Institutet, Stockholm, Sweden  
contributed samples and data, 
edited manuscript 
Sara.Margolin@karolin
ska.se 
201 1 
200 Frederique  Mariette PhD Fondazione Istituto FIRC di Oncologia Molecolare 
(IFOM), Milan, Italy; Cogentech Cancer Genetic Test 
Laboratory, Milan, Italy 
contributed samples and data, 
edited manuscript 
frederique.mariette@if
om.eu 
202 1 
201 Frederik  Marme PhD Department of Obstetrics and Gynecology, University 
of Heidelberg, Heidelberg, Germany; National Center 
for Tumor Diseases, University of Heidelberg, 
Heidelberg, Germany 
contributed samples and data, 
edited manuscript 
frederikmarme@gmail.
com 
203 4 
202 John W M Martens PhD Department of Medical Oncology, Erasmus MC 
Cancer Institute, Rotterdam, The Netherlands  
contributed samples and data, 
edited manuscript 
j.martens@erasmusmc
.nl 
204 1 
203 Leon  F A 
G 
Massuger PhD Department of Gynecology, Radboud University 
Medical Centre, Nijmegen, Netherlands  
contributed samples and data, 
edited manuscript 
leon.massuger@radbo
udumc.nl 
205 1 
204 Christine  Maugard MD Laboratoire de Diagnostic Génétique et Service 
d'Onco-hématologie, Hopitaux Universitaire de 
Strasbourg, CHRU Nouvel Hôpital Civil, Strasbourg, 
France 
contributed samples and data, 
edited manuscript 
christinemaugard@gm
ail.com 
206 4 
205 Sylvie  Mazoyer PhD INSERM U1052, CNRS UMR5286, Université Lyon 1, 
Centre de Recherche en Cancérologie de Lyon, Lyon, 
France 
contributed samples and data, 
edited manuscript 
sylvie.mazoyer@lyon.u
nicancer.fr 
207 1 
206 Lesley   McGuffog BS Centre for Cancer Genetic Epidemiology, Department 
of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK 
contributed samples and data, 
edited manuscript 
lesley@srl.cam.ac.uk 208 1 
207 Valerie  McGuire PhD Department of Health Research and Policy, Stanford 
University School of Medicine, Stanford, CA, USA  
contributed samples and data, 
edited manuscript 
vmcguire@stanford.ed
u 
209 1 
18 
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208 Catriona   McLean PhD Anatomical Pathology, The Alfred Hospital, Melbourne, 
Australia 
contributed samples and data, 
edited manuscript 
C.McLean@alfred.org.
au 
210 1 
209 Iain  McNeish MD Institute of Cancer Sciences, University of Glasgow, 
Wolfson Wohl Cancer Research Centre, Beatson 
Institute for Cancer Research, Glasgow, UK  
contributed samples and data, 
edited manuscript 
iain.mcneish@glasgow
.ac.uk 
211 1 
210 Alfons  Meindl PhD Department of Gynecology and Obstetrics, Division of 
Tumor Genetics, Klinikum rechts der Isar, Technical 
University Munich, Munich, Germany 
contributed samples and data, 
edited manuscript 
Alfons.Meindl@lrz.tu-
muenchen.de 
212 1 
211 Florence   Menegaux PhD INSERM U1018, CESP (Center for Research in 
Epidemiology and Population Health), Environmental 
Epidemiology of Cancer, Villejuif, France; University 
Paris-Sud, UMRS 1018, Villejuif, France 
contributed samples and data, 
edited manuscript 
florence.menegaux@in
serm.fr 
213 1 
212 Primitiva   Menéndez PhD Servicio de Anatomía Patológica, Hospital Monte 
Naranco, Oviedo, Spain 
contributed samples and data, 
edited manuscript 
tiva@hca.es 214 1 
213 Janusz  Menkiszak PhD Department of Surgical Gynecology and Gynecological 
Oncology of Adults and Adolescents, Pomeranian 
Medical University, Szczecin, Poland  
contributed samples and data, 
edited manuscript 
nbz@list.pl 215 1 
214 Usha  Menon PhD Gynaecological Cancer Research Centre, Department 
of Women’s Cancer, Institute for Women's Health, 
UCL, London, UK 
contributed samples and data, 
edited manuscript 
u.menon@ucl.ac.uk 216 1 
215 Arjen R Mensenkamp PhD Department of Human Genetics, Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands  
contributed samples and data, 
edited manuscript 
a.mensenkamp@gen.
umcn.nl 
217 1 
216 Nicola  Miller PhD School of Medicine, National University of Ireland, 
Galway, Ireland 
contributed samples and data, 
edited manuscript 
nicola.miller@nuigalwa
y.ie 
218 1 
217 Roger L Milne PhD Centre for Epidemiology and Biostatistics, School of 
Population and Global Health, University of Melbourne, 
Melbourne, VIC, Australia; Cancer Epidemiology 
Centre, Cancer Council Victoria, Melbourne, VIC, 
Australia 
contributed samples and data, 
edited manuscript 
roger.milne@cancervic
.org.au 
219 1 
218 Francesmar
y 
 Modugno PhD Department of Epidemiology, University of Pittsburgh 
Graduate School of Public Health, Pittsburgh, PA, 
USA; Department of Obstetrics, Gynecology and 
Reproductive Sciences, Division of Gynecologic 
Oncology, University of Pittsburgh School of Medicine, 
Pittsburgh, PA, USA; Womens Cancer Research 
Program, Magee-Women's Research Institute and 
University of Pittsburgh Cancer Institute, Pittsburgh, 
PA, USA 
contributed samples and data, 
edited manuscript 
fm@cs.cmu.edu 220 1 
219 Marco  Montagna PhD Immunology and Molecular Oncology Unit, Veneto 
Institute of Oncology IOV-IRCCS, Padua, Italy 
contributed samples and data, 
edited manuscript 
montagna@unipd.it 221 1 
220 Kirsten B Moysich PhD Department of Cancer Prevention and Control, 
Roswell Park Cancer Institute, Buffalo, NY, USA  
provided funding and 
contributed samples and data, 
edited manuscript 
kirsten.moysich@rosw
ellpark.org 
222 1 
221 Heiko  Müller PhD Division of Clinical Epidemiology and Aging Research, 
German Cancer Research Center, Heidelberg, 
Germany 
contributed samples and data, 
edited manuscript 
h1.mueller@web.de 223 2 
19 
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222 Anna Marie  Mulligan MD Department of Laboratory Medicine and Pathobiology, 
University of Toronto, Toronto, ON, Canada; 
Laboratory Medicine Program, University Health 
Network, Toronto, ON, Canada 
contributed samples and data, 
edited manuscript 
AnnaMarie.Mulligan@
uhn.ca  
224 1 
223 Taru A Muranen MS Department of Obstetrics and Gynecology, Helsinki 
University Central Hospital, University of Helsinki, 
Helsinki, Finland 
contributed samples and data, 
edited manuscript 
taru.a.muranen@helsi
nki.fi 
225 1 
224 Steven A Narod MD Women's College Research Institute, University of 
Toronto, Toronto, Ontario, Canada 
contributed samples and data, 
edited manuscript 
Steven.Narod@wchos
pital.ca 
226 1 
225 Katherine L Nathanson MD Department of Medicine, Perelman School of Medicine 
at the University of Pennsylvania, Philadelphia, PA, 
USA; Basser Research Centre, Abramson Cancer 
Center, The University of Pennsylvania Perelman 
School of Medicine, Philadelphia, PA, USA 
contributed samples and data, 
edited manuscript 
knathans@exchange.u
penn.edu 
227 1 
226 Roberta B Ness PhD The University of Texas School of Public Health, 
Houston, TX, USA 
contributed samples and data, 
edited manuscript 
roberta.b.ness@uth.tm
c.edu 
228 1 
227 Susan L Neuhausen PhD Department of Population Sciences, Beckman 
Research Institute of City of Hope, Duarte, CA, USA  
contributed samples and data, 
edited manuscript 
sneuhausen@coh.org 229 1 
228 Heli  Nevanlinna PhD Department of Obstetrics and Gynecology, Helsinki 
University Central Hospital, University of Helsinki, 
Helsinki, Finland 
contributed samples and data, 
edited manuscript 
Heli.Nevanlinna@hus.f
i 
230 1 
229 Patrick   Neven PhD Multidisciplinary Breast Center, University Hospital 
Leuven, University of Leuven, Belgium  
contributed samples and data, 
edited manuscript 
Patrick.Neven@uzleuv
en.be 
231 1 
230 Finn C Nielsen MD Center for Genomic Medicine, Rigshospitalet, 
Copenhagen University Hospital, Copenhagen, 
Denmark 
contributed samples and data, 
edited manuscript 
fcn@rh.dk 232 1 
231 Sune F Nielsen PhD Copenhagen General Population Study, Herlev 
Hospital, Copenhagen University Hospital, University 
of Copenhagen, Copenhagen, Denmark; Department 
of Clinical Biochemistry, Herlev Hospital, Copenhagen 
University Hospital, University of Copenhagen, 
Copenhagen, Denmark 
contributed samples and data, 
edited manuscript 
sune.fallgaard.nielsen
@regionh.dk 
233 1 
232 Børge G Nordestgaard PhD Copenhagen General Population Study, Herlev 
Hospital, Copenhagen University Hospital, University 
of Copenhagen, Copenhagen, Denmark; Department 
of Clinical Biochemistry, Herlev Hospital, Copenhagen 
University Hospital, University of Copenhagen, 
Copenhagen, Denmark 
contributed samples and data, 
edited manuscript 
boerge.nordestgaard@
regionh.dk  
234 1 
233 Robert L Nussbaum MD Department of Medicine and Institute for Human 
Genetics, University of California, San Francisco, CA, 
USA 
contributed samples and data, 
edited manuscript 
nussbaumr@humgen.
ucsf.edu 
235 1 
234 Kunle  Odunsi MD Department of Cancer Prevention and Control, 
Roswell Park Cancer Institute, Buffalo, NY, USA  
contributed samples and data, 
edited manuscript 
Kunle.Odunsi@roswell
park.org 
236 1 
235 Kenneth  Offit MD Clinical Genetics Service, Memorial Sloan-Kettering 
Cancer Center, New York, NY, USA 
provided funding and 
contributed samples and data, 
edited manuscript 
offitk@mskcc.org 237 1 
236 Edith  Olah PhD Department of Molecular Genetics, National Institute of 
Oncology, Budapest, Hungary 
contributed samples and data, 
edited manuscript 
e.olah@oncol.hu 238 1 
20 
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237 Olufunmilay
o 
I Olopade MD Center for Clinical Cancer Genetics and Global Health, 
University of Chicago Medical Center, Chicago, IL, 
USA 
contributed samples and data, 
edited manuscript 
folopade@medicine.bs
d.uchicago.edu 
239 1 
238 Janet E Olson PhD Department of Health Sciences Research, Division of 
Epidemiology, Mayo Clinic, Rochester, MN, USA  
contributed samples and data, 
edited manuscript 
olsonj@mayo.edu 240 1 
239 Sara H Olson PhD Department of Epidemiology and Biostatistics, 
Memorial Sloan-Kettering Cancer Center, New York, 
NY, USA 
contributed samples and data, 
edited manuscript 
olsons@mskcc.org 241 1 
240 Jan C Oosterwijk PhD University of Groningen, University Medical Center, 
Department of Genetics, Groningen, The Netherlands  
contributed samples and data, 
edited manuscript 
j.c.oosterwijk@medge
n.umcg.nl 
242 1 
241 Irene  Orlow PhD Department of Epidemiology and Biostatistics, 
Memorial Sloan-Kettering Cancer Center, New York, 
NY, USA 
contributed samples and data, 
edited manuscript 
orlowi@mskcc.org 243 1 
242 Nick  Orr PhD Breakthrough Breast Cancer Research Centre, 
Division of Breast Cancer Research, The Institute of 
Cancer Research, London, UK 
contributed samples and data, 
edited manuscript 
Nicholas.Orr@icr.ac.uk 244 1 
243 Sandra  Orsulic PhD Women's Cancer Program, Samuel Oschin 
Comprehensive Cancer Institute, Cedars-Sinai Medical 
Center, Los Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
sandra.orsulic@cshs.o
rg 
245 1 
244 Ana  Osorio PhD Human Genetics Group, Spanish National Cancer 
Research Centre (CNIO), Madrid, Spain; Biomedical 
Network on Rare Diseases (CIBERER), Madrid, Spain; 
Genetic and Molecular Epidemiology Group, Human 
Cancer Genetics Program, Spanish National Cancer 
Research Centre (CNIO), Madrid, Spain 
contributed samples and data, 
edited manuscript 
aosorio@cnio.es 246 1 
245 Laura  Ottini MD Department of Molecular Medicine, Sapienza 
University, Rome, Italy 
contributed samples and data, 
edited manuscript 
laura.ottini@uniroma1.i
t 
247 1 
246 James  Paul PhD Cancer Research UK Clinical Trials Unit, The Beatson 
West of Scotland Cancer Centre, Glasgow, UK  
contributed samples and data, 
edited manuscript 
James.Paul@glasgow.
ac.uk 
250 1 
247 Celeste L Pearce PhD Department of Preventive Medicine, Keck School of 
Medicine, University of Southern California, Los 
Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
pearce_l@med.usc.ed
u 
251 1 
248 Inge Sokilde  Pedersen PhD Section of Molecular Diagnostics, Department of 
Clinical Biochemistry, Aalborg University Hospital, 
Aalborg, Denmark 
contributed samples and data, 
edited manuscript 
isp@rn.dk 252 1 
249 Bernard  Peissel MD Unit of Medical Genetics, Department of Preventive 
and Predictive Medicine, Fondazione Istituto di 
Ricovero e Cura a Carattere Scientifico Istituto 
Nazionale Tumori (INT), Milan, Italy 
contributed samples and data, 
edited manuscript 
bernard.peissel@istitut
otumori.mi.it 
253 1 
250 Tanja  Pejovic PhD Department of Obstetrics and Gynecology, Oregon 
Health and Science University, Portland, OR, USA; 
Knight Cancer Institute, Oregon Health and Science 
University, Portland, OR, USA 
contributed samples and data, 
edited manuscript 
pejovict@ohsu.edu 254 1 
251 Liisa M Pelttari PhD Department of Obstetrics and Gynecology, Helsinki 
University Central Hospital, University of Helsinki, 
Helsinki, Finland 
contributed samples and data, 
edited manuscript 
liisa.pelttari@helsinki.fi 255 1 
21 
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252 Jo  Perkins PhD Centre for Cancer Genetic Epidemiology, Department 
of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK 
contributed samples and data, 
edited manuscript 
jp410@medschl.cam.a
c.uk 
256 2 
253 Jenny  Permuth-Wey PhD Department of Cancer Epidemiology, H. Lee Moffitt 
Cancer Center and Research Institute, Tampa, FL, 
USA 
contributed samples and data, 
edited manuscript 
jenny.wey@moffitt.org 257 1 
254 Paolo  Peterlongo PhD Fondazione Istituto FIRC di Oncologia Molecolare 
(IFOM), Milan, Italy 
contributed samples and data, 
edited manuscript 
paolo.peterlongo@ifo
m-ieo-campus.it 
258 1 
255 Julian  Peto PhD Non-Communicable Disease Epidemiology 
Department, London School of Hygiene and Tropical 
Medicine, London, UK 
contributed samples and data, 
edited manuscript 
Julian.Peto@lshtm.ac.
uk 
259 1 
256 Catherine M Phelan MD Department of Cancer Epidemiology, H. Lee Moffitt 
Cancer Center and Research Institute, Tampa, FL, 
USA 
provided funding and 
contributed samples and data, 
edited manuscript 
Catherine.Phelan@mo
ffitt.org 
260 1 
257 Kelly-Anne  Phillips PhD Centre for Epidemiology and Biostatistics, School of 
Population and Global Health, University of Melbourne, 
Melbourne, VIC, Australia; Sir Peter MacCallum 
Department of Oncology, The University of Melbourne, 
Australia; Division of Cancer Medicine, Peter 
MacCallum Cancer Centre, Melbourne, Australia; 
Department of Medicine, St Vincent’s Hospital, The 
University of Melbourne, Victoria, Australia 
contributed samples and data, 
edited manuscript 
Kelly.Phillips@peterma
c.org 
261 1 
258 Marion  Piedmonte MA NRG Oncology Statistics and Data Management 
Center, Buffalo, NY, USA 
contributed samples and data, 
edited manuscript 
marion.piedmonte@g
mail.com 
262 1 
259 Malcolm C Pike PhD Department of Preventive Medicine, Keck School of 
Medicine, University of Southern California, Los 
Angeles, CA, USA; Department of Epidemiology and 
Biostatistics, Memorial Sloan-Kettering Cancer Center, 
New York, NY, USA 
contributed samples and data, 
edited manuscript 
pikem@mskcc.org 263 1 
260 Radka  Platte BS Centre for Cancer Genetic Epidemiology, Department 
of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK 
contributed samples and data, 
edited manuscript 
rp356@medschl.cam.a
c.uk 
264 1 
261 Joanna  Plisiecka-Halasa MD Department of Pathology and Laboratory Diagnostics 
the Maria Sklodowska-Curie Memorial Cancer Center 
and Institute of Oncology, Warsaw, Poland  
contributed samples and data, 
edited manuscript 
jopliha@coi.waw.pl 265 1 
262 Elizabeth M Poole PhD Department of Epidemiology, Harvard School of Public 
Health, Boston, MA, USA; Channing Division of 
Network Medicine, Harvard Medical School and 
Brigham and Women's Hospital, Boston, MA, USA 
contributed samples and data, 
edited manuscript 
liz.poole@channing.ha
rvard.edu 
266 1 
263 Bruce  Poppe MD Center for Medical Genetics, Ghent University, Ghent, 
Belgium 
contributed samples and data, 
edited manuscript 
Bruce.Poppe@UGent.
be  
267 1 
264 Katri  Pylkäs PhD Laboratory of Cancer Genetics and Tumor Biology, 
Department of Clinical Genetics, University of Oulu, 
Oulu University Hospital, Oulu, Finland; Biocenter 
Oulu, University of Oulu, Oulu, Finland 
contributed samples and data, 
edited manuscript 
katri.pylkas@oulu.fi 268 1 
22 
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265 Paolo  Radice PhD Unit of Molecular Bases of Genetic Risk and Genetic 
Testing, Department of Preventive and Predictive 
Medicine, Fondazione Istituto di Ricovero e Cura a 
Carattere Scientifico, Istituto Nazionale Tumori (INT), 
Milan, Italy 
contributed samples and data, 
edited manuscript 
Paolo.Radice@istitutot
umori.mi.it 
269 1 
266 Susan J Ramus PhD Department of Preventive Medicine, Keck School of 
Medicine, University of Southern California, Los 
Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
sramus@usc.edu 270 1 
267 Timothy R Rebbeck PhD Basser Research Centre, Abramson Cancer Center, 
The University of Pennsylvania Perelman School of 
Medicine, Philadelphia, PA, USA; Center for Clinical 
Epidemiology and Biostatistics, The University of 
Pennsylvania Perelman School of Medicine, 
Philadelphia, PA, USA 
contributed samples and data, 
edited manuscript 
rebbeck@exchange.up
enn.edu 
271 1 
268 Malcolm  W R Reed MD Sheffield Cancer Research Centre, Department of 
Oncology, University of Sheffield, Sheffield, UK 
contributed samples and data, 
edited manuscript 
m.reed@bsms.ac.uk 272 4 
269 Gad  Rennert MD Clalit National Israeli Cancer Control Center, Haifa, 
Israel; Department of Community Medicine and 
Epidemiology, Carmel Medical Center and B. 
Rappaport Faculty of Medicine, Technion, Haifa, Israel 
contributed samples and data, 
edited manuscript 
rennert@tx.technion.a
c.il 
273 1 
270 Harvey A Risch PhD Department of Chronic Disease Epidemiology, Yale 
School of Public Health, New Haven, CT, USA  
contributed samples and data, 
edited manuscript 
harvey.risch@yale.edu 274 1 
271 Mark  Robson MD Clinical Genetics Service, Memorial Sloan-Kettering 
Cancer Center, New York, NY, USA 
contributed samples and data, 
edited manuscript 
robsonm@mskcc.org 275 1 
272 Gustavo C Rodriguez MD NorthShore University Health System, University of 
Chicago, Evanston, IL, USA 
contributed samples and data, 
edited manuscript 
grodriguez@northshor
e.org  
276 1 
273 Atocha  Romero PhD Molecular Oncology Laboratory, Hospital Clinico San 
Carlos, Madrid, Spain 
contributed samples and data, 
edited manuscript 
atocha10@hotmail.co
m 
277 1 
274 Mary Anne  Rossing PhD Department of Epidemiology, University of 
Washington, Seattle, WA, USA; Program in 
Epidemiology, Division of Public Health Sciences, Fred 
Hutchinson Cancer Research Center, Seattle, WA, 
USA 
contributed samples and data, 
edited manuscript 
mrossing@fhcrc.org 278 1 
275 Joseph H Rothstein PhD Department of Health Research and Policy, Stanford 
University School of Medicine, Stanford, CA, USA  
contributed samples and data, 
edited manuscript 
joe.rothstein@stanford
.edu 
279 1 
276 Anja  Rudolph PhD Division of Cancer Epidemiology, German Cancer 
Research Center (DKFZ), Heidelberg, Germany  
contributed samples and data, 
edited manuscript 
a.rudolph@dkfz.de 280 1 
277 Ingo  Runnebaum PhD Department of Gynecology, Jena University Hospital, 
Jena, Germany 
contributed samples and data, 
edited manuscript 
INGO.RUNNEBAUM@
med.uni-jena.de 
281 1 
278 Ritu  Salani MD Ohio State University, Columbus, OH, USA contributed samples and data, 
edited manuscript 
ritu.salani@osumc.edu 282 1 
279 Helga B Salvesen PhD Department of Gynecology and Obstetrics, Haukeland 
University Hospital, Bergen, Norway; Department of 
Clinical Science, University of Bergen, Bergen, Norway 
contributed samples and data, 
edited manuscript 
helga.salvesen@uib.n
o 
283 1 
280 Elinor J Sawyer PhD Division of Cancer Studies, NIHR Comprehensive 
Biomedical Research Centre, Guy's & St. Thomas' 
NHS Foundation Trust in partnership with King's 
College London, London, UK 
contributed samples and data, 
edited manuscript 
Elinor.Sawyer@gstt.nh
s.uk 
284 1 
23 
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281 Joellen M Schildkraut PhD Department of Community and Family Medicine, Duke 
University Medical Center, Durham, NC, USA; Cancer 
Prevention, Detection and Control Research Program, 
Duke Cancer Institute, Durham, NC, USA 
provided funding and 
contributed samples and data, 
edited manuscript 
schil001@mc.duke.ed
u 
285 1 
282 Marjanka K Schmidt PhD Netherlands Cancer Institute, Antoni van 
Leeuwenhoek Hospital, Amsterdam, The Netherlands  
contributed samples and data, 
edited manuscript 
mk.schmidt@nki.nl 286 1 
283 Rita K Schmutzler MD Centre of Familial Breast and Ovarian Cancer, 
Department of Gynaecology and Obstetrics, University 
Hospital of Cologne, Cologne, Germany; Centre for 
Molecular Medicine Cologne (CMMC), University 
Hospital of Cologne, Cologne, Germany 
contributed samples and data, 
edited manuscript 
Rita.Schmutzler@uk-
koeln.de 
287 1 
284 Andreas  Schneeweiss PhD Department of Obstetrics and Gynecology, University 
of Heidelberg, Heidelberg, Germany; National Center 
for Tumor Diseases, University of Heidelberg, 
Heidelberg, Germany 
contributed samples and data, 
edited manuscript 
Andreas.Schneeweiss
@med.uni-
heidelberg.de 
288 1 
285 Minouk J Schoemaker  PhD Division of Genetics and Epidemiology, The Institute of 
Cancer Research, Sutton, Surrey, UK  
contributed samples and data, 
edited manuscript 
Minouk.schoemaker@i
cr.ac.uk 
289 1 
286 Michael G Schrauder PhD University Breast Center Franconia, Department of 
Gynecology and Obstetrics, University Hospital 
Erlangen, Erlangen, Germany 
contributed samples and data, 
edited manuscript 
michael.schrauder@uk
-erlangen.de 
290 1 
287 Fredrick  Schumacher PhD Department of Preventive Medicine, Keck School of 
Medicine, University of Southern California, Los 
Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
fschumac@usc.edu 291 1 
288 Ira  Schwaab MD Institut für Humangenetik Wiesbaden, Wiesbaden, 
Germany 
contributed samples and data, 
edited manuscript 
iraschwaab@gmx.de 292 2 
289 Giulietta  Scuvera MD Unit of Medical Genetics, Department of Preventive 
and Predictive Medicine, Fondazione Istituto di 
Ricovero e Cura a Carattere Scientifico Istituto 
Nazionale Tumori (INT), Milan, Italy 
contributed samples and data, 
edited manuscript 
giulietta.scuvera@istitu
totumori.mi.it 
293 1 
290 Thomas A Sellers PhD Department of Cancer Epidemiology, H. Lee Moffitt 
Cancer Center and Research Institute, Tampa, FL, 
USA 
provided funding and 
contributed samples and data, 
edited manuscript 
Thomas.Sellers@moffi
tt.org 
294 1 
291 Gianluca  Severi PhD Centre for Epidemiology and Biostatistics, School of 
Population and Global Health, University of Melbourne, 
Melbourne, VIC, Australia; Cancer Epidemiology 
Centre, Cancer Council Victoria, Melbourne, VIC, 
Australia; Department of Epidemiology and Preventive 
Medicine, Monash University, Melbourne, VIC, 
Australia 
contributed samples and data, 
edited manuscript 
Gianluca.severi@canc
ervic.org.au 
295 1 
292 Caroline M Seynaeve PhD Department of Medical Oncology, Erasmus MC 
Cancer Institute, Rotterdam, The Netherlands  
contributed samples and data, 
edited manuscript 
c.seynaeve@erasmus
mc.nl 
296 1 
293 Mitul  Shah PhD Centre for Cancer Genetic Epidemiology, Department 
of Oncology, University of Cambridge, Cambridge, UK  
contributed samples and data, 
edited manuscript 
ms483@medschl.cam.
ac.uk 
297 1 
294 Martha  Shrubsole PhD Division of Epidemiology, Department of Medicine, 
Vanderbilt Epidemiology Center, Vanderbilt-Ingram 
Cancer Center, Vanderbilt University School of 
Medicine, Nashville, TN, USA 
contributed samples and data, 
edited manuscript 
martha.shrubsole@va
nderbilt.edu 
298 1 
24 
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295 Nadeem  Siddiqui PhD Department of Gynecological Oncology, Glasgow 
Royal Infirmary, Glasgow, UK 
contributed samples and data, 
edited manuscript 
nadeem.siddiqui@ggc.
scot.nhs.uk 
299 1 
296 Weiva  Sieh PhD Department of Health Research and Policy, Stanford 
University School of Medicine, Stanford, CA, USA  
contributed samples and data, 
edited manuscript 
wsieh@stanford.edu 300 1 
297 Jacques  Simard PhD Centre Hospitalier Universitaire de Québec Research 
Center and Laval University, Quebec, Canada  
contributed samples and data, 
edited manuscript 
jacques.simard@crchu
l.ulaval.ca 
301 1 
298 Christian F Singer MD Department of Obstetrics and Gynecology, 
Comprehensive Cancer Center, Medical University of 
Vienna, Vienna, Austria 
contributed samples and data, 
edited manuscript 
christian.singer@medu
niwien.ac.at 
302 2 
299 Olga M Sinilnikova PhD INSERM U1052, CNRS UMR5286, Université Lyon 1, 
Centre de Recherche en Cancérologie de Lyon, Lyon, 
France; Unité Mixte de Génétique Constitutionnelle 
des Cancers Fréquents, Hospices Civils de Lyon, 
Centre Léon Bérard, Lyon, France 
contributed samples and data, 
edited manuscript 
sylvie.mazoyer@lyon.u
nicancer.fr 
303 1 
300 Dominiek   Smeets PhD Laboratory for Translational Genetics, Department of 
Oncology, University of Leuven, Belgium; Vesalius 
Research Center (VRC), VIB, Leuven, Belgium 
contributed samples and data, 
edited manuscript 
Dominiek.Smeets@vib
-kuleuven.be 
304 1 
301 Christof  Sohn PhD Department of Obstetrics and Gynecology, University 
of Heidelberg, Heidelberg, Germany 
contributed samples and data, 
edited manuscript 
Christof.Sohn@med.u
ni-heidelberg.de 
305 1 
302 Maria  Soller MD Department of Clinical Genetics, University and 
Regional Laboratories, Lund University Hospital, Lund, 
Sweden  
contributed samples and data, 
edited manuscript 
maria.soller@med.lu.s
e 
306 1 
303 Honglin  Song PhD Centre for Cancer Genetic Epidemiology, Department 
of Oncology, University of Cambridge, Cambridge, UK  
contributed samples and data, 
edited manuscript 
hs310@medschl.cam.
ac.uk 
307 1 
304 Penny  Soucy PhD Centre Hospitalier Universitaire de Québec Research 
Center and Laval University, Quebec, Canada  
contributed samples and data, 
edited manuscript 
penny.soucy@crchul.u
laval.ca 
308 1 
305 Melissa C Southey PhD Genetic Epidemiology Laboratory, Department of 
Pathology, The University of Melbourne, Melbourne, 
Australia 
contributed samples and data, 
edited manuscript 
msouthey@unimelb.ed
u.au 
309 1 
306 Christa  Stegmaier PhD Saarland Cancer Registry, Saarbrücken, Germany contributed samples and data, 
edited manuscript 
krebsregister@gbe-
ekr.saarland.de 
310 1 
307 Dominique  Stoppa-Lyonnet MD Institut Curie, Department of Tumour Biology, Paris, 
France; Institut Curie, INSERM U830, Paris, France; 
Université Paris Descartes, Sorbonne Paris Cité, 
France 
contributed samples and data, 
edited manuscript 
dominique.stoppa-
lyonnet@curie.net 
311 3 
308 Lara  Sucheston PhD Department of Cancer Prevention and Control, 
Roswell Park Cancer Institute, Buffalo, NY, USA  
contributed samples and data, 
edited manuscript 
Lara.Sucheston@rosw
ellpark.org 
312 1 
309   SWE-BRCA  Department of Oncology, Lund University, Lund, 
Sweden  
contributed samples and data, 
edited manuscript 
ake.borg@med.lu.se 313 1 
310 Anthony  Swerdlow PhD Division of Genetics and Epidemiology, The Institute of 
Cancer Research, Sutton, Surrey, UK; Division of 
Breast Cancer Research, The Institute of Cancer 
Research, Sutton, Surrey, UK 
contributed samples and data, 
edited manuscript 
Anthony.Swerdlow@ic
r.ac.uk 
314 1 
311 Ingvild L Tangen MD Department of Gynecology and Obstetrics, Haukeland 
University Hospital, Bergen, Norway; Department of 
Clinical Science, University of Bergen, Bergen, Norway 
contributed samples and data, 
edited manuscript 
Ingvild.Tangen@k2.uib
.no 
316 1 
25 
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312 Muy-Kheng  Tea MD Department of Obstetrics and Gynecology, 
Comprehensive Cancer Center, Medical University of 
Vienna, Vienna, Austria 
contributed samples and data, 
edited manuscript 
muy-
kheng.tea@meduniwie
n.ac.at 
317 1 
313 Manuel R Teixeira MD Department of Genetics, Portuguese Oncology 
Institute, Porto, Portugal; Biomedical Sciences Institute 
(ICBAS), Porto University, Porto, Portugal 
contributed samples and data, 
edited manuscript 
manuel.teixeira@ipopo
rto.min-saude.pt 
318 1 
314 Kathryn L Terry PhD Obstetrics and Gynecology Epidemiology Center, 
Brigham and Women's Hospital and Harvard Medical 
School, Boston, MA, USA; Department of 
Epidemiology, Harvard School of Public Health, 
Boston, MA, USA 
contributed samples and data, 
edited manuscript 
kterry@partners.org  319 1 
315 Mary Beth  Terry PhD Department of Epidemiology, Columbia University, 
New York, NY, USA 
contributed samples and data, 
edited manuscript 
mt146@columbia.edu 320 1 
316 Mads  Thomassen PhD Department of Clinical Genetics, Odense University 
Hospital, Odense, Denmark 
contributed samples and data, 
edited manuscript 
mads.thomassen@rsy
d.dk 
321 1 
317 Pamela J Thompson PhD Samuel Oschin Comprehensive Cancer Institute, 
Cedars Sinai Medical Center, Los Angeles, CA, USA  
contributed samples and data, 
edited manuscript 
Pamela.Thompson@c
shs.org 
322 1 
318 Laima  Tihomirova PhD Latvian Biomedical Research and Study Centre, Riga, 
Latvia 
contributed samples and data, 
edited manuscript 
laima@biomed.lu.lv 323 1 
319 Marc  Tischkowitz MD Program in Cancer Genetics, Departments of Human 
Genetics and Oncology, McGill University, Montreal, 
Quebec, Canada 
contributed samples and data, 
edited manuscript 
mdt33@medschl.cam.
ac.uk 
324 1 
320 Amanda  Ewa
rt 
Toland PhD Divison of Human Cancer Genetics, Departments of 
Internal Medicine and Molecular Virology, Immunology 
and Medical Genetics, Comprehensive Cancer Center, 
The Ohio State University, Columbus, OH, USA 
contributed samples and data, 
edited manuscript 
amanda.toland@osum
c.edu 
325 1 
321 Rob A E 
M 
Tollenaar PhD Department of Surgical Oncology, Leiden University 
Medical Center, Leiden, The Netherlands  
contributed samples and data, 
edited manuscript 
r.a.e.m.tollenaar@lum
c.nl 
326 1 
322 Ian  Tomlinson PhD Welcome Trust Centre for Human Genetics, University 
of Oxford, UK; Oxford Biomedical Research Centre, 
University of Oxford, UK 
contributed samples and data, 
edited manuscript 
iant@well.ox.ac.uk 327 1 
323 Diana  Torres PhD Molecular Genetics of Breast Cancer, German Cancer 
Research Center (DKFZ), Heidelberg, Germany  
contributed samples and data, 
edited manuscript 
dianatlopez@yahoo.co
m 
328 1 
324 Thérèse  Truong PhD INSERM U1018, CESP (Center for Research in 
Epidemiology and Population Health), Environmental 
Epidemiology of Cancer, Villejuif, France; University 
Paris-Sud, UMRS 1018, Villejuif, France 
contributed samples and data, 
edited manuscript 
therese.truong@inser
m.fr 
329 1 
325 Helen  Tsimiklis PhD Genetic Epidemiology Laboratory, Department of 
Pathology, The University of Melbourne, Melbourne, 
Australia 
contributed samples and data, 
edited manuscript 
htsi@unimelb.edu.au 330 1 
326 Nadine  Tung MD Department of Medical Oncology, Beth Israel 
Deaconess Medical Center, Boston, MA, USA  
contributed samples and data, 
edited manuscript 
ntung@bidmc.harvard.
edu 
331 1 
327 Shelley S Tworoger PhD Department of Epidemiology, Harvard School of Public 
Health, Boston, MA, USA; Channing Division of 
Network Medicine, Harvard Medical School and 
Brigham and Women's Hospital, Boston, MA, USA 
contributed samples and data, 
edited manuscript 
nhsst@channing.harva
rd.edu 
332 1 
328 Jonathan P Tyrer PhD Centre for Cancer Genetic Epidemiology, Department 
of Oncology, University of Cambridge, Cambridge, UK  
contributed samples and data, 
edited manuscript 
jpt34@medschl.cam.a
c.uk 
333 1 
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329 Celine M Vachon PhD Department of Health Sciences Research, Division of 
Epidemiology, Mayo Clinic, Rochester, MN, USA  
contributed samples and data, 
edited manuscript 
vachon.celine@mayo.
edu 
334 1 
330 Laura  J Van ’t Veer PhD Netherlands Cancer Institute, Antoni van 
Leeuwenhoek Hospital, Amsterdam, The Netherlands  
contributed samples and data, 
edited manuscript 
l.vt.veer@nki.nl 335 1 
331 Anne M van Altena PhD Department of Gynecology, Radboud University 
Medical Centre, Nijmegen, Netherlands  
contributed samples and data, 
edited manuscript 
annevana@hotmail.co
m 
336 1 
332 C  J Van Asperen PhD Department of Clinical Genetics, Leiden University 
Medical Center, Leiden, The Netherlands  
contributed samples and data, 
edited manuscript 
c.j.van_Asperen@lumc
.nl 
337 1 
333 David  van den Berg PhD Department of Preventive Medicine, Keck School of 
Medicine, University of Southern California, Los 
Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
dvandenb@usc.edu 338 1 
334 Ans  M W van den 
Ouweland 
PhD Department of Clinical Genetics, Erasmus University 
Medical Center, Rotterdam, The Netherlands  
contributed samples and data, 
edited manuscript 
a.vandenouweland@er
asmusmc.nl 
339 1 
335 Helena C van Doorn PhD Department of Gynecology, Erasmus MC Cancer 
Institute, Rotterdam, The Netherlands  
contributed samples and data, 
edited manuscript 
h.vandoorn@erasmus
mc.nl 
340 1 
336 Els  Van 
Nieuwenhuysen 
PhD Division of Gynecologic Oncology , Department of 
Obstetrics and Gynaecology, University Hospitals 
Leuven, Leuven, Belgium; Leuven Cancer Institute, 
University Hospitals Leuven, Leuven, Belgium 
contributed samples and data, 
edited manuscript 
Els.Vannieuwenhuyse
n@uzleuven.be 
341 1 
337 Elizabeth J van Rensburg PhD Department of Genetics, University of Pretoria, 
Pretoria, South Africa 
contributed samples and data, 
edited manuscript 
Lizette.vanrensburg@
up.ac.za 
342 1 
338 Ignace  Vergote PhD Division of Gynecologic Oncology , Department of 
Obstetrics and Gynaecology, University Hospitals 
Leuven, Leuven, Belgium; Leuven Cancer Institute, 
University Hospitals Leuven, Leuven, Belgium 
contributed samples and data, 
edited manuscript 
Ignace.vergote@uzleu
ven.be 
343 1 
339 Senno  Verhoef PhD Netherlands Cancer Institute, Antoni van 
Leeuwenhoek Hospital, Amsterdam, The Netherlands  
contributed samples and data, 
edited manuscript 
s.verhoef@nki.nl 344 1 
340 Robert A Vierkant MS Department of Health Sciences Research, Division of 
Biomedical Statistics and Informatics, Mayo Clinic, 
Rochester, MN, USA 
contributed samples and data, 
edited manuscript 
vierkant.robert@mayo.
edu 
345 1 
341 Joseph  Vijai PhD Clinical Genetics Research Laboratory, Memorial 
Sloan-Kettering Cancer Center, New York, NY, USA  
contributed samples and data, 
edited manuscript 
josephv@mskcc.org 346 1 
342 Allison F Vitonis PhD Obstetrics and Gynecology Epidemiology Center, 
Brigham and Women's Hospital and Harvard Medical 
School, Boston, MA, USA 
contributed samples and data, 
edited manuscript 
avitonis@partners.org 347 1 
343 Anna  von Wachenfeldt MD Department of Oncology, Karolinska University 
Hospital, Stockholm, Sweden  
contributed samples and data, 
edited manuscript 
annavwachenfeldt@ho
tmail.com 
348 4 
344 Christine  Walsh MD Women's Cancer Program, Samuel Oschin 
Comprehensive Cancer Institute, Cedars-Sinai Medical 
Center, Los Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
christine.walsh@cshs.
org 
349 1 
345 Qin   Wang PhD Centre for Cancer Genetic Epidemiology, Department 
of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK 
contributed samples and data, 
edited manuscript 
qw232@medschl.cam.
ac.uk 
350 1 
346 Shan  Wang-Gohrke PhD Department of Obstetrics and Gynecology, University 
of Ulm, Ulm, Germany 
contributed samples and data, 
edited manuscript 
shan.wang-
gohrke@uniklinik-
ulm.de 
352 1 
27 
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347 Barbara  Wappenschmidt PhD Centre of Familial Breast and Ovarian Cancer, 
Department of Gynaecology and Obstetrics, University 
Hospital of Cologne, Cologne, Germany; Centre for 
Molecular Medicine Cologne (CMMC), University 
Hospital of Cologne, Cologne, Germany 
contributed samples and data, 
edited manuscript 
Barbara.Wappenschmi
dt@uk-koeln.de 
353 1 
348 Maren   Weischer PhD Copenhagen General Population Study, Herlev 
Hospital, Copenhagen University Hospital, University 
of Copenhagen, Copenhagen, Denmark; Department 
of Clinical Biochemistry, Herlev Hospital, Copenhagen 
University Hospital, University of Copenhagen, 
Copenhagen, Denmark 
contributed samples and data, 
edited manuscript 
maren.weischer@regio
nh.dk 
354 2 
349 Jeffrey N Weitzel MD Clinical Cancer Genetics, City of Hope, Duarte, CA, 
USA 
contributed samples and data, 
edited manuscript 
jweitzel@coh.org 355 1 
350 Caroline   Weltens PhD Multidisciplinary Breast Center, University Hospital 
Leuven, University of Leuven, Belgium  
contributed samples and data, 
edited manuscript 
Caroline.Weltens@uzl
euven.be 
356 1 
351 Nicolas  Wentzensen PhD Division of Cancer Epidemiology and Genetics, 
National Cancer Institute, Bethesda, MD, USA  
contributed samples and data, 
edited manuscript 
wentzenn@mail.nih.go
v 
357 1 
352 Alice S Whittemore PhD Department of Health Research and Policy, Stanford 
University School of Medicine, Stanford, CA, USA 
contributed samples and data, 
edited manuscript 
alicesw@stanford.edu 358 1 
353 Lynne R Wilkens PhD Cancer Epidemiology Program, University of Hawaii 
Cancer Center, Honolulu, HI, USA 
contributed samples and data, 
edited manuscript 
lynne@cc.hawaii.edu 359 1 
354 Robert  Winqvist PhD Laboratory of Cancer Genetics and Tumor Biology, 
Department of Clinical Genetics, University of Oulu, 
Oulu University Hospital, Oulu, Finland; Biocenter 
Oulu, University of Oulu, Oulu, Finland 
contributed samples and data, 
edited manuscript 
robert.winqvist@oulu.fi 360 1 
355 Anna H Wu PhD Department of Preventive Medicine, Keck School of 
Medicine, University of Southern California, Los 
Angeles, CA, USA 
contributed samples and data, 
edited manuscript 
Anna.Wu@med.usc.ed
u 
361 1 
356 Xifeng  Wu PhD Department of Epidemiology, The University of Texas 
MD Anderson Cancer Center, Houston, TX, USA  
contributed samples and data, 
edited manuscript 
xwu@mdanderson.org 362 1 
357 Hannah P Yang PhD Division of Cancer Epidemiology and Genetics, 
National Cancer Institute, Bethesda, MD, USA  
contributed samples and data, 
edited manuscript 
yanghan@mail.nih.gov 363 1 
358 Daniela  Zaffaroni PhD Unit of Medical Genetics, Department of Preventive 
and Predictive Medicine, Fondazione Istituto di 
Ricovero e Cura a Carattere Scientifico Istituto 
Nazionale Tumori (INT), Milan, Italy 
contributed samples and data, 
edited manuscript 
daniela.zaffaroni@istit
utotumori.mi.it 
364 1 
359 M Pilar  Zamora PhD Servicio de Oncología Médica, Hospital Universitario 
La Paz, Madrid, Spain 
contributed samples and data, 
edited manuscript 
zamorapilar@gmail.co
m 
365 1 
360 Wei  Zheng PhD Division of Epidemiology, Department of Medicine, 
Vanderbilt Epidemiology Center, Vanderbilt-Ingram 
Cancer Center, Vanderbilt University School of 
Medicine, Nashville, TN, USA 
contributed samples and data, 
edited manuscript 
wei.zheng@Vanderbilt.
Edu 
366 1 
361 Argyrios  Ziogas PhD Department of Epidemiology, Center for Cancer 
Genetics Research and Prevention, School of 
Medicine, University of California Irvine, Irvine, CA, 
USA 
contributed samples and data, 
edited manuscript 
aziogas@uci.edu 367 1 
28 
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362 Georgia  Chenevix-Trench PhD Department of Genetics, QIMR Berghofer Medical 
Research Institute, Brisbane, Australia  
conducted analysis, provided 
funding, and contributed 
samples and data, edited 
manuscript 
Georgia.Trench@qimr.
edu.au 
368 1 
363 Paul  D P Pharoah MD, PhD Centre for Cancer Genetic Epidemiology, Department 
of Oncology, University of Cambridge, Cambridge, UK  
wrote the initial manuscript, 
conducted analysis, provided 
funding, and contributed 
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ABSTRACT 516 
Objective. Clinical genetic testing is commercially available for rs61764370, an inherited 517 
variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with 518 
increased ovarian and breast cancer risk as well as with survival time. However, prior studies, 519 
emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated 520 
ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.  521 
Methods. Centralized genotyping and analysis was performed for 140,012 women enrolled 522 
in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), 523 
the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and 524 
the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7,904 BRCA2 mutation 525 
carriers).  526 
Results. We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94–1.04, 527 
p=0.74) or breast cancer (OR=0.98, 95% CI 0.94–1.01, p=0.19) and results were consistent 528 
among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97–1.23, p=0.14, breast 529 
cancer HR=1.04, 95% CI 0.97–1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71–1.13, 530 
p=0.34, breast cancer HR=1.06, 95% CI 0.94–1.19, p=0.35). Null results were also obtained for 531 
associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83–1.07, p=0.38), 532 
breast cancer (HR=0.96, 95% CI 0.87–1.06, p=0.38), and all other previously-reported 533 
associations.  534 
Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with 535 
clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical 536 
utility related to the prediction or management of these cancers.  537 
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INTRODUCTION 538 
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that negatively 539 
regulate gene expression by binding partially complementary sites in the 3′ untranslated regions 540 
(UTRs) of their target mRNAs. In this way, miRNAs control many cancer-related biological 541 
pathways involved in cell proliferation, differentiation, and apoptosis [1]. To date, several inherited 542 
variants in microRNAs or miRNA target sites have been reported to confer increased cancer risks 543 
[2]. One such variant is located in the 3′ UTR of the KRAS gene (rs61764370 T>G) for which the 544 
rarer G allele has been reported to confer an increased risk of ovarian, breast, and lung cancer [3-545 
7] as well as endometriosis [8], although not consistently [9-11].  546 
For ovarian cancer, the rs61764370 G allele was also reported to be associated with 547 
increased risk (320 cases, 328 controls). Further increased risks were observed among 23 BRCA1 548 
mutation carriers and 31 women with familial ovarian cancer, but without BRCA1 or BRCA2 549 
mutations [3]. In contrast, no association with ovarian cancer risk was seen in another, much larger 550 
study, based on 8,669 cases, 10,012 controls, and 2,682 BRCA1 mutation carriers [9]. One 551 
criticism on the latter study was that some of the genotype data were for rs17388148, an imputed 552 
proxy for rs61764370; even though rs17388148 is highly correlated with rs61764370 (r2=0.97) and 553 
was imputed with high accuracy (r2=0.977) [12, 13]. The minor allele of rs61764370 was also 554 
associated with shorter survival time in a study of 279 ovarian cancer patients diagnosed after age 555 
52 years with platinum-resistant disease (28 resistant, 263 not resistant) and with sub-optimal 556 
debulking surgery after neoadjuvant chemotherapy (7 sub-optimal, 109 optimal) [14]. However, 557 
another study observed no association between rs61764370 and  ovarian cancer outcome (329 558 
cases) [15].  559 
For breast cancer, a borderline significant increased frequency of the rs61764370 G allele 560 
was observed in 268 BRCA1 mutation carriers with breast cancer, but not in 127 estrogen receptor 561 
(ER)-negative familial non-BRCA1/BRCA2 breast cancer patients [5]. However, in a subsequent 562 
study, the variant was reported to be associated with increased risk of ER/PR negative disease (80 563 
cases, 470 controls), as well as with triple negative breast cancer diagnosed before age 52 (111 564 
cases, 250 controls), regardless of BRCA1 mutation status [6]. The validity of these findings has 565 
been questioned given the very small sample sizes and the number of subgroups tested [16, 17]. 566 
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Another report found no association with sporadic or familial breast cancer risk (695 combined 567 
cases, 270 controls), but found that the variant was associated with ERBB2-positive and high 568 
grade disease, based on 153 cases who used post-menopausal hormone replacement therapy 569 
[18].  570 
It has also been reported, based on 232 women with both primary ovarian and breast 571 
cancer, that the frequency of the G allele at rs61764370 was increased for those who were 572 
screened negative for BRCA1 and BRCA2 (92 cases), particularly among those enrolled within two 573 
years of their ovarian cancer diagnosis (to minimize survival bias, 30 cases), those diagnosed with 574 
post-menopausal ovarian cancer (63 cases), those with a family history of ovarian or breast cancer 575 
(24 cases), and those with a third primary cancer (16 cases) [4].  576 
This notable lack of consistency in findings between studies might be expected when 577 
appropriate levels of statistical significance are not used to declare positive findings from multiple 578 
small subgroup comparisons or post-hoc hypotheses [19]. In this respect, the dangers of subgroup 579 
analyses in the context of clinical trials are well-recognized [20]. These are important caveats, 580 
particularly since a genetic test for rs61764370 is currently marketed in the US for risk prediction 581 
testing to women who are at increased risk for developing ovarian and/or breast cancer or women 582 
who have been diagnosed with either ovarian or breast cancer themselves [21]. In general, much 583 
larger studies, with sufficient power to detect positive findings at much more stringent levels of 584 
statistical significance ought to be required to establish the clinical validity of a genetic test. 585 
Therefore, we conducted centralized genotyping of rs61764370 and other variants in the genomic 586 
region around the KRAS gene in 140,012 women to examine associations with risk and clinical 587 
outcome of ovarian and breast cancer.  588 
 589 
METHODS 590 
Study Participants  591 
The following three consortia contributed to these analyses: the Ovarian Cancer 592 
Association Consortium (OCAC: 41 studies, Supplementary Table S1) [22], the Breast Cancer 593 
Association Consortium (BCAC: 37 studies, Supplementary Table S2) [23], and the Consortium of 594 
Modifiers of BRCA1 and BRCA2 (CIMBA: 55 studies, Supplementary Table S3) [24, 25]. OCAC 595 
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and BCAC consisted of case-control studies of unrelated women, and CIMBA consisted of studies 596 
of women with germline deleterious BRCA1 or BRCA2 mutations primarily identified through 597 
clinical genetics centers. For the purpose of the current analyses, only participants of European 598 
ancestry were included. Following genotyping, quality control exclusions (described below), and 599 
analysis-specific exclusions, data from the following women were available for analysis: 46,173 600 
OCAC participants (15,357 patients with invasive epithelial ovarian cancer and 30,816 controls), 601 
71,170 BCAC participants (33,530 patients with invasive breast cancer and 37,640 controls), and 602 
22,669 CIMBA participants (for ovarian cancer analyses: 2,332 affected and 12,433 unaffected 603 
BRCA1 carriers, 599 affected and 7,305 unaffected BRCA2 carriers; for breast cancer analyses: 604 
7,543 affected and 7,222 unaffected BRCA1 carriers, 4,138 affected and 3,766 unaffected BRCA2 605 
carriers). For OCAC, overall and progression-free survival data were available for 3,096 patients 606 
from 13 studies. Overall survival data were available for 28,471 patients from 26 BCAC studies 607 
and for 2,623 mutation carriers with breast cancer from 11 CIMBA studies (excluding studies with 608 
less than ten deaths) as described previously [26, 27]. Each study was approved by its relevant 609 
governing research ethics committee, and all study participants provided written informed consent. 610 
 611 
Genotyping and Imputation  612 
Genotyping for rs61764370 was performed using the custom iCOGS Illumina Infinium 613 
iSelect BeadChip, as previously described [22-25]. In total, DNA from 185,443 women of varying 614 
ethnic background was genotyped (47,630 OCAC participants, 114,255 BCAC participants, 23,558 615 
CIMBA participants), along with HapMap2 DNAs for European, African, and Asian populations. 616 
Genotype data were also available for three OCAC genome-wide association studies (UK GWAS, 617 
US GWAS, Mayo GWAS) that had been genotyped using either the Illumina Human610-Quad 618 
Beadchip (12,607 participants) [28] or the Illumina HumanOmni2.5-8 Beadchip (883 participants). 619 
Raw intensity data files underwent centralized genotype calling and quality control [22-25]. 620 
HapMap2 samples were used to identify women with predicted European intercontinental ancestry; 621 
among these women, a set of over 37,000 unlinked markers was used to perform principal 622 
component (PC) analysis [29]. The first five and seven European PCs were found to control 623 
adequately for residual population stratification in OCAC and BCAC data, respectively. Samples 624 
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with low conversion rate, extreme heterozygosity, non-female sex, or one of a first-degree relative 625 
pair (the latter for OCAC and BCAC only) were excluded. Variants were excluded if they were 626 
monomorphic or had a call rate <95% (minor allele frequency (MAF) >0.05) or <99% (MAF <0.05), 627 
deviation from Hardy-Weinberg equilibrium (p <10-7), or >2% duplicate discordance.  628 
In addition to rs61764370, 54 variants within 100 kb on either side of KRAS on 629 
chromosome 12 (25,258,179 to 25,503,854 bp in GRCh37.p12) were genotyped. Moreover, to 630 
provide a common set of variants across the region for analysis in all the data sets, we also used 631 
imputation to infer genotypes for another 1,056 variants and for variants that failed genotyping.  632 
We performed imputation separately for OCAC samples BCAC samples, BRCA1 mutation carriers, 633 
BRCA2 mutation carriers, and for each of the OCAC GWAS. We imputed variants from the 1000 634 
Genomes Project data using the v3 April 2012 release as the reference panel [30]. To improve 635 
computation efficiency we initially used a two-step procedure, which involved pre-phasing using 636 
the SHAPEIT software [31] in the first step and imputation of the phased data in the second. We 637 
used the IMPUTE version 2 software [32] for the imputation for all studies with the exception of the 638 
US GWAS for which we used the MACH algorithm implemented in the minimac software version 639 
2012.8.15 and MACH version 1.0.18 [33]. We excluded variants from association analyses if their 640 
imputation accuracy was r2<0.30 or their MAF was <0.005, resulting in 974 variants genotyped and 641 
imputed for OCAC, 989 variants genotyped and imputed for BCAC, and 1,001 variants genotyped 642 
and imputed for CIMBA, including rs61764370 (Supplementary Tables S5, S6, and S7).  643 
 644 
Analysis   645 
Genotypes were coded for genotype dosage as 0, 1, or 2, based on the number of copies 646 
of the minor allele. For ovarian cancer case-control analysis (i.e., OCAC studies), logistic 647 
regression provided estimated risks of invasive epithelial ovarian cancer with odds ratios (ORs) 648 
and 95% confidence intervals (CIs) adjusting for study, age, and the five European PCs. Subgroup 649 
analyses were conducted by histology, family ovarian and breast cancer history, menopausal 650 
status, time between ovarian cancer diagnosis and recruitment, and history of multiple primary 651 
cancers. For breast cancer case-control analysis (i.e., BCAC studies), the association between 652 
genotype and invasive breast cancer risk was evaluated by logistic regression, adjusting for study, 653 
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age, and the seven European PCs, providing ORs and 95% CIs. Additional subgroup analyses 654 
were based on receptor status, first-degree family ovarian and breast cancer history, BRCA1 and 655 
BRCA2 mutation status, enrollment within two years of diagnosis, menopausal status (i.e. last 656 
menstruation longer than twelve months ago), age at diagnosis less than 52 years, and history of 657 
hormone replacement therapy use (i.e. longer than twelve months use). Risk analysis for BRCA1 658 
and BRCA2 mutation carriers (i.e. CIMBA studies) was done using a Cox proportional hazard 659 
model to estimate hazard ratios (HRs) per copy of the minor allele, with age as follow-up time and 660 
stratified by country of residence; US and Canadian strata were further subdivided by self-reported 661 
Ashkenazi Jewish ancestry [24, 25]. A weighted cohort approach was applied to correct for 662 
potential testing bias due to overrepresentation of cases in the study population [34]. We used 663 
robust variance estimation to allow for the non-independence of carriers within the same family 664 
[35]. To assess associations with ovarian cancer risk, mutation carriers were followed from birth 665 
until ovarian cancer diagnosis (event), a risk-reducing salpingo-oophorectomy (RRSO) or the age 666 
at enrollment, whichever occurred first. We also performed analyses restricted to women 667 
diagnosed or censored within two years before their enrollment. To assess associations with 668 
breast cancer risk, mutation carriers were followed from birth until a breast cancer diagnosis (i.e. 669 
either ductal carcinoma in situ or invasive breast cancer), ovarian cancer diagnosis, a risk-reducing 670 
bilateral prophylactic mastectomy or the age at enrollment, whichever occurred first. 671 
Survival analysis of OCAC patients used Cox proportional hazards models estimating HRs 672 
and 95% CIs considering overall survival as well as progression-free survival following ovarian 673 
cancer diagnosis. Overall survival was adjusted for age at diagnosis, the five European PCs, 674 
histology, grade, FIGO stage, residual disease after debulking surgery, and stratified by study, left 675 
truncating at the date of study entry and right censoring at five years to minimize events due to 676 
other causes. Progression-free survival was analyzed as for overall survival, but without 677 
adjustment for age and right censoring, and was defined as the time between the date of histologic 678 
diagnosis and the first confirmed sign of disease recurrence or progression, based on GCIG 679 
(Gynecological Cancer InterGroup) criteria [36]. We also performed subgroup analysis of patients 680 
suboptimally debulked after cytoreductive surgery (residual disease >1cm) and of post-681 
menopausal patients (age at diagnosis >52 years). Survival analysis of BCAC patients used Cox 682 
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proportional hazard models estimating HRs and 95% CIs considering overall and breast cancer-683 
specific survival following breast cancer diagnosis. Models were adjusted for age at diagnosis, 684 
tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy, and stratified by study, 685 
left-truncating at the date of study entry and right censoring at ten years. In addition, we performed 686 
subgroup analysis on ER-positive and ER-negative patients. For CIMBA breast cancer patients 687 
associations between genotype and overall survival were evaluated using Cox proportional hazard 688 
models estimating HRs and 95% CIs. Models were adjusted for age at diagnosis, tumor size, nodal 689 
status, grade, adjuvant hormonal and/or chemotherapy, and preventive bilateral oophorectomy and 690 
stratified by study, left-truncating at the date of study entry and right censoring at twenty years. 691 
Analyses were performed using STATA version 12.0 (StataCorp, Texas, USA).  692 
 693 
RESULTS 694 
The results of the overall analysis as well as the subgroup analyses investigating the 695 
association between the minor allele at rs61764370 and ovarian cancer risk, breast cancer risk, 696 
and ovarian and breast cancer risks in BRCA1 and BRCA2 mutation carriers are shown in Table 1. 697 
Associations with clinical outcomes in and ovarian and breast cancer patients including BRCA1 698 
and BRCA2 mutation carriers are shown in Table 2 and Supplementary Table S4.  699 
We found no evidence for association between the rs61764370 G allele and ovarian or 700 
breast cancer risk. The most statistically significant association was observed for risk of low-grade 701 
serous ovarian cancer (n=485; OR 0.76, 95% CI 0.59-0.97, p=0.031), but this finding was not 702 
significant after Bonferroni correction for multiple testing. We also evaluated the association for 703 
additional specific subgroups in which an association with rs61764370 had been reported 704 
previously [3-6]. Ovarian cancer subgroups considered BRCA1 mutation carriers as well as 705 
BRCA1 and BRCA2 screened-negative patients with first degree family histories of breast or 706 
ovarian cancer and patients who had been diagnosed with breast cancer before their ovarian 707 
cancer diagnoses. For breast cancer these included, amongst others, BRCA1 mutation carriers, 708 
patients diagnosed with ER- and PR-negative tumors, and patients diagnosed with triple negative 709 
tumors before age 52 years. Importantly, we observed no evidence for association of rs61764370 710 
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with any of these subgroups (detailed in Table 1), with all ORs close to unity and very narrow CIs 711 
including unity. 712 
Similarly, case-only analyses did not reveal any associations between rs61764370 713 
genotype and ovarian and breast cancer clinical features or outcome (Table 2 and Supplementary 714 
Table S4). For example, the previously reported association between rs61764370 and risk of 715 
ERBB2-positive and high grade breast cancer in hormone replacement therapy users [18] was not 716 
replicated (Supplementary Table S4), and in ovarian cancer analyses we found no evidence of 717 
reduced survival among patients diagnosed after age 52 years or patients with suboptimal 718 
debulking after cytoreductive surgery (Table 2) [14]. The G allele of rs61764370 was also not 719 
associated with survival of breast cancer patients (Table 2). 720 
Finally, we evaluated the association between the primary phenotypes of interest and 721 
common genetic variation (MAF>0.02) in the genomic region of KRAS (i.e., within 100 kb on either 722 
side of the gene), using imputed and genotyped data on 974 variants for OCAC, 989 variants for 723 
BCAC, and 1,001 variants genotyped and imputed for CIMBA (Supplementary Tables S5, S6, and 724 
S7). We found no evidence of association for any of these variants, including rs61764370 and 725 
rs17388148, with these phenotypes that would withstand Bonferroni correction for multiple testing, 726 
as detailed in Supplementary Tables S5, S6, and S7 and shown in regional association plots 727 
(Figure 1). 728 
 729 
DISCUSSION 730 
Our analysis of 140,012 women genotyped for inherited variants in the KRAS region 731 
provides definitive clarification of the role of these variants in ovarian and breast cancer 732 
susceptibility and outcome.  We have found no evidence to support an association between 733 
rs61764370 and ovarian or breast cancer risk, or clinical outcomes in patients with ovarian or 734 
breast cancer. In the absence of any association and with ORs close to unity we would not 735 
typically consider sub-group analyses, particularly sub-groups for which differential associations 736 
would not be expected to occur. However, given the previous positive associations reported for a 737 
myriad of different subgroups, we tested for association among each of these subgroups and 738 
found no evidence to support the previously reported associations.   739 
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Our study has notable strengths. The vast majority (i.e. >95%) of the samples were 740 
genotyped using the same genotyping platform and employing a common approach to genotype 741 
calling and quality control; additional samples used denser arrays and nearly identical procedures. 742 
The very large sample sizes for all the major phenotypes of interest provide substantial statistical 743 
power to exclude any clinically relevant associated risks for the major phenotypes of interest 744 
(Figure 2). The null results found here are thus not due to lack of statistical power, and this 745 
analysis also had greater than 80% power to detect association for most of the subgroups, 746 
although for some subgroups it was not possible to exclude modest risks. In contrast to the current 747 
findings, other genetic association analyses using the same genotyping platform and the same 748 
studies as included here have identified more than 90 common germline variants associated with 749 
ovarian or breast cancer risk at p< 5 x 10-8 [22, 23, 37]. While critiques on a previous null KRAS 750 
report have suggested that inclusion of male controls, use of “prevalent” cases, and reliance on a 751 
surrogate genetic variant may have led to falsely negative conclusions, these are not issues in the 752 
present data set. Rather, we demonstrate the importance of international collaboration to identify 753 
true associations as well as to refute false associations, an equally important objective. 754 
The rise of individualized medicine including the use of panels of common variants to 755 
predict cancer risk more accurately than using family history alone holds great promise [38]. For 756 
example, the 31 prostate cancer susceptibility alleles confirmed as of 2011 can be combined to 757 
identify men in the top one percent of the risk distribution having a 3.2-fold increased risk [39]. 758 
Prediction has since then improved with now over 70 prostate cancer susceptibility alleles [40] and 759 
the utility of these genetic tests is currently under clinical evaluation. Similar clinical examination in 760 
ovarian and breast cancer is not far behind, with now over 18 and 77 confirmed susceptibility 761 
alleles, respectively, for these cancers [22, 23]. The genotype at rs61764370, however, does not 762 
predict ovarian or breast cancer risk, even among particular subgroups of women or for particular 763 
subtypes of disease, nor is it a marker of differential outcome following diagnosis with these 764 
cancers. Therefore, genetic test results for rs61764370 should not be used to counsel women 765 
about their ovarian or breast cancer risks or outcome. Our results highlight the dangers of 766 
developing clinical tests without appropriate data from carefully conducted, large-scale studies to 767 
establish clinical validity.  768 
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 1335 
Table 2.  Associations between KRAS rs61764370 and outcome in ovarian and breast 1336 
cancer. 1337 
Ovarian cancer analyses used OCAC data adjusted for age at diagnosis (overall survival only), the 1338 
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FIGURE LEGENDS 1347 
Figure 1. Regional association plots for variants within the genomic region 100 kb either 1348 
side of KRAS and risk of ovarian and breast cancer.  1349 
X-axis position is referent to position (bp) on chromosome 12, build GRCh37.p12; yellow line 1350 
indicates position of KRAS; red triangle indicates rs61764370. Y-axis is –log10(p-values) from 1351 
association tests for risk of A) ER-negative breast cancer, B) ER-positive breast cancer, C) Breast 1352 
cancer in BRCA1 mutation carriers, D) Breast cancer in BRCA2 mutation carriers, E) Epithelial 1353 
ovarian cancer, F) Epithelial ovarian cancer in BRCA1 mutation carriers, and G) Epithelial ovarian 1354 
cancer in BRCA2 mutation carriers. 1355 
 1356 
Figure 2. Power curve for modest risk variants according to the total sample size.  1357 
X-axis is total sample size for which case-control ratio is 1:1. Y- axis is the statistical power (range 1358 
0·5-1·0) for variants given a range of risks, assuming alpha=0·01 and minor allele frequency 0·09. 1359 
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ABSTRACT 519 
Objective. Clinical genetic testing is commercially available for rs61764370, an inherited 520 
variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with 521 
increased ovarian and breast cancer risk as well as with survival time. However, prior studies, 522 
emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated 523 
ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.  524 
Methods. Centralized genotyping and analysis was performed for 140,012 women enrolled 525 
in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), 526 
the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and 527 
the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7,904 BRCA2 mutation 528 
carriers).  529 
Results. We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94–1.04, 530 
p=0.74) or breast cancer (OR=0.98, 95% CI 0.94–1.01, p=0.19) and results were consistent 531 
among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97–1.23, p=0.14, breast 532 
cancer HR=1.04, 95% CI 0.97–1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71–1.13, 533 
p=0.34, breast cancer HR=1.06, 95% CI 0.94–1.19, p=0.35). Null results were also obtained for 534 
associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83–1.07, p=0.38), 535 
breast cancer (HR=0.96, 95% CI 0.87–1.06, p=0.38), and all other previously-reported 536 
associations.  537 
Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with 538 
clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical 539 
utility related to the prediction or management of these cancers.  540 
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INTRODUCTION 541 
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that negatively 542 
regulate gene expression by binding partially complementary sites in the 3′ untranslated regions 543 
(UTRs) of their target mRNAs. In this way, miRNAs control many cancer-related biological 544 
pathways involved in cell proliferation, differentiation, and apoptosis [1]. To date, several inherited 545 
variants in microRNAs or miRNA target sites have been reported to confer increased cancer risks 546 
[2]. One such variant is located in the 3′ UTR of the KRAS gene (rs61764370 T>G) for which the 547 
rarer G allele has been reported to confer an increased risk of ovarian, breast, and lung cancer [3-548 
7] as well as endometriosis [8], although not consistently [9-11].  549 
For ovarian cancer, the rs61764370 G allele was also reported to be associated with 550 
increased risk (320 cases, 328 controls). Further increased risks were observed among 23 BRCA1 551 
mutation carriers and 31 women with familial ovarian cancer, but without BRCA1 or BRCA2 552 
mutations [3]. In contrast, no association with ovarian cancer risk was seen in another, much larger 553 
study, based on 8,669 cases, 10,012 controls, and 2,682 BRCA1 mutation carriers [9]. One 554 
criticism on the latter study was that some of the genotype data were for rs17388148, an imputed 555 
proxy for rs61764370; even though rs17388148 is highly correlated with rs61764370 (r2=0.97) and 556 
was imputed with high accuracy (r2=0.977) [12, 13]. The minor allele of rs61764370 was also 557 
associated with shorter survival time in a study of 279 ovarian cancer patients diagnosed after age 558 
52 years with platinum-resistant disease (28 resistant, 263 not resistant) and with sub-optimal 559 
debulking surgery after neoadjuvant chemotherapy (7 sub-optimal, 109 optimal) [14]. However, 560 
another study observed no association between rs61764370 and  ovarian cancer outcome (329 561 
cases) [15].  562 
For breast cancer, a borderline significant increased frequency of the rs61764370 G allele 563 
was observed in 268 BRCA1 mutation carriers with breast cancer, but not in 127 estrogen receptor 564 
(ER)-negative familial non-BRCA1/BRCA2 breast cancer patients [5]. However, in a subsequent 565 
study, the variant was reported to be associated with increased risk of ER/PR negative disease (80 566 
cases, 470 controls), as well as with triple negative breast cancer diagnosed before age 52 (111 567 
cases, 250 controls), regardless of BRCA1 mutation status [6]. The validity of these findings has 568 
been questioned given the very small sample sizes and the number of subgroups tested [16, 17]. 569 
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Another report found no association with sporadic or familial breast cancer risk (695 combined 570 
cases, 270 controls), but found that the variant was associated with ERBB2-positive and high 571 
grade disease, based on 153 cases who used post-menopausal hormone replacement therapy 572 
[18].  573 
It has also been reported, based on 232 women with both primary ovarian and breast 574 
cancer, that the frequency of the G allele at rs61764370 was increased for those who were 575 
screened negative for BRCA1 and BRCA2 (92 cases), particularly among those enrolled within two 576 
years of their ovarian cancer diagnosis (to minimize survival bias, 30 cases), those diagnosed with 577 
post-menopausal ovarian cancer (63 cases), those with a family history of ovarian or breast cancer 578 
(24 cases), and those with a third primary cancer (16 cases) [4].  579 
This notable lack of consistency in findings between studies might be expected when 580 
appropriate levels of statistical significance are not used to declare positive findings from multiple 581 
small subgroup comparisons or post-hoc hypotheses [19]. In this respect, the dangers of subgroup 582 
analyses in the context of clinical trials are well-recognized [20]. These are important caveats, 583 
particularly since a genetic test for rs61764370 is currently marketed in the US for risk prediction 584 
testing to women who are at increased risk for developing ovarian and/or breast cancer or women 585 
who have been diagnosed with either ovarian or breast cancer themselves [21]. In general, much 586 
larger studies, with sufficient power to detect positive findings at much more stringent levels of 587 
statistical significance ought to be required to establish the clinical validity of a genetic test. 588 
Therefore, we conducted centralized genotyping of rs61764370 and other variants in the genomic 589 
region around the KRAS gene in 140,012 women to examine associations with risk and clinical 590 
outcome of ovarian and breast cancer.  591 
 592 
METHODS 593 
Study Participants  594 
The following three consortia contributed to these analyses: the Ovarian Cancer 595 
Association Consortium (OCAC: 41 studies, Supplementary Table S1) [22], the Breast Cancer 596 
Association Consortium (BCAC: 37 studies, Supplementary Table S2) [23], and the Consortium of 597 
Modifiers of BRCA1 and BRCA2 (CIMBA: 55 studies, Supplementary Table S3) [24, 25]. OCAC 598 
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and BCAC consisted of case-control studies of unrelated women, and CIMBA consisted of studies 599 
of women with germline deleterious BRCA1 or BRCA2 mutations primarily identified through 600 
clinical genetics centers. For the purpose of the current analyses, only participants of European 601 
ancestry were included. Following genotyping, quality control exclusions (described below), and 602 
analysis-specific exclusions, data from the following women were available for analysis: 46,173 603 
OCAC participants (15,357 patients with invasive epithelial ovarian cancer and 30,816 controls), 604 
71,170 BCAC participants (33,530 patients with invasive breast cancer and 37,640 controls), and 605 
22,669 CIMBA participants (for ovarian cancer analyses: 2,332 affected and 12,433 unaffected 606 
BRCA1 carriers, 599 affected and 7,305 unaffected BRCA2 carriers; for breast cancer analyses: 607 
7,543 affected and 7,222 unaffected BRCA1 carriers, 4,138 affected and 3,766 unaffected BRCA2 608 
carriers). For OCAC, overall and progression-free survival data were available for 3,096 patients 609 
from 13 studies. Overall survival data were available for 28,471 patients from 26 BCAC studies 610 
and for 2,623 mutation carriers with breast cancer from 11 CIMBA studies (excluding studies with 611 
less than ten deaths) as described previously [26, 27]. Each study was approved by its relevant 612 
governing research ethics committee, and all study participants provided written informed consent. 613 
 614 
Genotyping and Imputation  615 
Genotyping for rs61764370 was performed using the custom iCOGS Illumina Infinium 616 
iSelect BeadChip, as previously described [22-25]. In total, DNA from 185,443 women of varying 617 
ethnic background was genotyped (47,630 OCAC participants, 114,255 BCAC participants, 23,558 618 
CIMBA participants), along with HapMap2 DNAs for European, African, and Asian populations. 619 
Genotype data were also available for three OCAC genome-wide association studies (UK GWAS, 620 
US GWAS, Mayo GWAS) that had been genotyped using either the Illumina Human610-Quad 621 
Beadchip (12,607 participants) [28] or the Illumina HumanOmni2.5-8 Beadchip (883 participants). 622 
Raw intensity data files underwent centralized genotype calling and quality control [22-25]. 623 
HapMap2 samples were used to identify women with predicted European intercontinental ancestry; 624 
among these women, a set of over 37,000 unlinked markers was used to perform principal 625 
component (PC) analysis [29]. The first five and seven European PCs were found to control 626 
adequately for residual population stratification in OCAC and BCAC data, respectively. Samples 627 
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with low conversion rate, extreme heterozygosity, non-female sex, or one of a first-degree relative 628 
pair (the latter for OCAC and BCAC only) were excluded. Variants were excluded if they were 629 
monomorphic or had a call rate <95% (minor allele frequency (MAF) >0.05) or <99% (MAF <0.05), 630 
deviation from Hardy-Weinberg equilibrium (p <10-7), or >2% duplicate discordance.  631 
In addition to rs61764370, 54 variants within 100 kb on either side of KRAS on 632 
chromosome 12 (25,258,179 to 25,503,854 bp in GRCh37.p12) were genotyped. Moreover, to 633 
provide a common set of variants across the region for analysis in all the data sets, we also used 634 
imputation to infer genotypes for another 1,056 variants and for variants that failed genotyping.  635 
We performed imputation separately for OCAC samples, BCAC samples, BRCA1 mutation 636 
carriers, BRCA2 mutation carriers, and for each of the OCAC GWAS. We imputed variants from 637 
the 1000 Genomes Project data using the v3 April 2012 release as the reference panel [30]. To 638 
improve computation efficiency we initially used a two-step procedure, which involved pre-phasing 639 
using the SHAPEIT software [31] in the first step and imputation of the phased data in the second. 640 
We used the IMPUTE version 2 software [32] for the imputation for all studies with the exception of 641 
the US GWAS for which we used the MACH algorithm implemented in the minimac software 642 
version 2012.8.15 and MACH version 1.0.18 [33]. We excluded variants from association analyses 643 
if their imputation accuracy was r2<0.30 or their MAF was <0.005, resulting in 974 variants 644 
genotyped and imputed for OCAC, 989 variants genotyped and imputed for BCAC, and 1,001 645 
variants genotyped and imputed for CIMBA, including rs61764370 (Supplementary Tables S5, S6, 646 
and S7).  647 
 648 
Analysis   649 
Genotypes were coded for genotype dosage as 0, 1, or 2, based on the number of copies 650 
of the minor allele. For ovarian cancer case-control analysis (i.e., OCAC studies), logistic 651 
regression provided estimated risks of invasive epithelial ovarian cancer with odds ratios (ORs) 652 
and 95% confidence intervals (CIs) adjusting for study, age, and the five European PCs. Subgroup 653 
analyses were conducted by histology, family ovarian and breast cancer history, menopausal 654 
status, time between ovarian cancer diagnosis and recruitment, and history of multiple primary 655 
cancers. For breast cancer case-control analysis (i.e., BCAC studies), the association between 656 
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genotype and invasive breast cancer risk was evaluated by logistic regression, adjusting for study, 657 
age, and the seven European PCs, providing ORs and 95% CIs. Additional subgroup analyses 658 
were based on receptor status, first-degree family ovarian and breast cancer history, BRCA1 and 659 
BRCA2 mutation status, enrollment within two years of diagnosis, menopausal status (i.e. last 660 
menstruation longer than twelve months ago), age at diagnosis less than 52 years, and history of 661 
hormone replacement therapy use (i.e. longer than twelve months use). Risk analysis for BRCA1 662 
and BRCA2 mutation carriers (i.e. CIMBA studies) was done using a Cox proportional hazard 663 
model to estimate hazard ratios (HRs) per copy of the minor allele, with age as follow-up time and 664 
stratified by country of residence; US and Canadian strata were further subdivided by self-reported 665 
Ashkenazi Jewish ancestry [24, 25]. A weighted cohort approach was applied to correct for 666 
potential testing bias due to overrepresentation of cases in the study population [34]. We used 667 
robust variance estimation to allow for the non-independence of carriers within the same family 668 
[35]. To assess associations with ovarian cancer risk, mutation carriers were followed from birth 669 
until ovarian cancer diagnosis (event), a risk-reducing salpingo-oophorectomy (RRSO) or the age 670 
at enrollment, whichever occurred first. We also performed analyses restricted to women 671 
diagnosed or censored within two years before their enrollment. To assess associations with 672 
breast cancer risk, mutation carriers were followed from birth until a breast cancer diagnosis (i.e. 673 
either ductal carcinoma in situ or invasive breast cancer), ovarian cancer diagnosis, a risk-reducing 674 
bilateral prophylactic mastectomy or the age at enrollment, whichever occurred first. 675 
Survival analysis of OCAC patients used Cox proportional hazards models estimating HRs 676 
and 95% CIs considering overall survival as well as progression-free survival following ovarian 677 
cancer diagnosis. Overall survival was adjusted for age at diagnosis, the five European PCs, 678 
histology, grade, FIGO stage, residual disease after debulking surgery, and stratified by study, left 679 
truncating at the date of study entry and right censoring at five years to minimize events due to 680 
other causes. Progression-free survival was analyzed as for overall survival, but without 681 
adjustment for age and right censoring, and was defined as the time between the date of histologic 682 
diagnosis and the first confirmed sign of disease recurrence or progression, based on GCIG 683 
(Gynecological Cancer InterGroup) criteria [36]. We also performed subgroup analysis of patients 684 
suboptimally debulked after cytoreductive surgery (residual disease >1cm) and of post-685 
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menopausal patients (age at diagnosis >52 years). Survival analysis of BCAC patients used Cox 686 
proportional hazard models estimating HRs and 95% CIs considering overall and breast cancer-687 
specific survival following breast cancer diagnosis. Models were adjusted for age at diagnosis, 688 
tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy, and stratified by study, 689 
left-truncating at the date of study entry and right censoring at ten years. In addition, we performed 690 
subgroup analysis on ER-positive and ER-negative patients. For CIMBA breast cancer patients 691 
associations between genotype and overall survival were evaluated using Cox proportional hazard 692 
models estimating HRs and 95% CIs. Models were adjusted for age at diagnosis, tumor size, nodal 693 
status, grade, adjuvant hormonal and/or chemotherapy, and preventive bilateral oophorectomy and 694 
stratified by study, left-truncating at the date of study entry and right censoring at twenty years. 695 
Analyses were performed using STATA version 12.0 (StataCorp, Texas, USA).  696 
 697 
RESULTS 698 
The results of the overall analysis as well as the subgroup analyses investigating the 699 
association between the minor allele at rs61764370 and ovarian cancer risk, breast cancer risk, 700 
and ovarian and breast cancer risks in BRCA1 and BRCA2 mutation carriers are shown in Table 1. 701 
Associations with clinical outcomes in and ovarian and breast cancer patients including BRCA1 702 
and BRCA2 mutation carriers are shown in Table 2 and Supplementary Table S4.  703 
We found no evidence for association between the rs61764370 G allele and ovarian or 704 
breast cancer risk. The most statistically significant association was observed for risk of low-grade 705 
serous ovarian cancer (n=485; OR 0.76, 95% CI 0.59-0.97, p=0.031), but this finding was not 706 
significant after Bonferroni correction for multiple testing. We also evaluated the association for 707 
additional specific subgroups in which an association with rs61764370 had been reported 708 
previously [3-6]. Ovarian cancer subgroups considered BRCA1 mutation carriers as well as 709 
BRCA1 and BRCA2 screened-negative patients with first degree family histories of breast or 710 
ovarian cancer and patients who had been diagnosed with breast cancer before their ovarian 711 
cancer diagnoses. For breast cancer these included, amongst others, BRCA1 mutation carriers, 712 
patients diagnosed with ER- and PR-negative tumors, and patients diagnosed with triple negative 713 
tumors before age 52 years. Importantly, we observed no evidence for association of rs61764370 714 
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with any of these subgroups (detailed in Table 1), with all ORs close to unity and very narrow CIs 715 
including unity. 716 
Similarly, case-only analyses did not reveal any associations between rs61764370 717 
genotype and ovarian and breast cancer clinical features or outcome (Table 2 and Supplementary 718 
Table S4). For example, the previously reported association between rs61764370 and risk of 719 
ERBB2-positive and high grade breast cancer in hormone replacement therapy users [18] was not 720 
replicated (Supplementary Table S4), and in ovarian cancer analyses we found no evidence of 721 
reduced survival among patients diagnosed after age 52 years or patients with suboptimal 722 
debulking after cytoreductive surgery (Table 2) [14]. The G allele of rs61764370 was also not 723 
associated with survival of breast cancer patients (Table 2). 724 
Finally, we evaluated the association between the primary phenotypes of interest and 725 
common genetic variation (MAF>0.02) in the genomic region of KRAS (i.e., within 100 kb on either 726 
side of the gene), using imputed and genotyped data on 974 variants for OCAC, 989 variants for 727 
BCAC, and 1,001 variants genotyped and imputed for CIMBA (Supplementary Tables S5, S6, and 728 
S7). We found no evidence of association for any of these variants, including rs61764370 and 729 
rs17388148, with these phenotypes that would withstand Bonferroni correction for multiple testing, 730 
as detailed in Supplementary Tables S5, S6, and S7 and shown in regional association plots 731 
(Figure 1). 732 
 733 
DISCUSSION 734 
Our analysis of 140,012 women genotyped for inherited variants in the KRAS region 735 
provides definitive clarification of the role of these variants in ovarian and breast cancer 736 
susceptibility and outcome.  We have found no evidence to support an association between 737 
rs61764370 and ovarian or breast cancer risk, or clinical outcomes in patients with ovarian or 738 
breast cancer. In the absence of any association and with ORs close to unity we would not 739 
typically consider sub-group analyses, particularly sub-groups for which differential associations 740 
would not be expected to occur. However, given the previous positive associations reported for a 741 
myriad of different subgroups, we tested for association among each of these subgroups and 742 
found no evidence to support the previously reported associations.   743 
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Our study has notable strengths. The vast majority (i.e. >95%) of the samples were 744 
genotyped using the same genotyping platform and employing a common approach to genotype 745 
calling and quality control; additional samples used denser arrays and nearly identical procedures. 746 
The very large sample sizes for all the major phenotypes of interest provide substantial statistical 747 
power to exclude any clinically relevant associated risks for the major phenotypes of interest 748 
(Figure 2). The null results found here are thus not due to lack of statistical power, and this 749 
analysis also had greater than 80% power to detect association for most of the subgroups, 750 
although for some subgroups it was not possible to exclude modest risks. In contrast to the current 751 
findings, other genetic association analyses using the same genotyping platform and the same 752 
studies as included here have identified more than 90 common germline variants associated with 753 
ovarian or breast cancer risk at p< 5 x 10-8 [22, 23, 37]. While critiques on a previous null KRAS 754 
report have suggested that inclusion of male controls, use of “prevalent” cases, and reliance on a 755 
surrogate genetic variant may have led to falsely negative conclusions, these are not issues in the 756 
present data set. Rather, we demonstrate the importance of international collaboration to identify 757 
true associations as well as to refute false associations, an equally important objective. 758 
The rise of individualized medicine including the use of panels of common variants to 759 
predict cancer risk more accurately than using family history alone holds great promise [38]. For 760 
example, the 31 prostate cancer susceptibility alleles confirmed as of 2011 (at p<5x10-8) can be 761 
combined to identify men in the top one percent of the risk distribution having a 3.2-fold increased 762 
risk [39]. Prediction has since then improved with now over 70 prostate cancer susceptibility alleles 763 
[40] and the utility of these genetic tests is currently under clinical evaluation. Similar clinical 764 
examination in ovarian and breast cancer is not far behind, with now over 18 and 77 confirmed 765 
susceptibility alleles, respectively, for these cancers [22, 23]. The genotype at rs61764370, 766 
however, does not predict ovarian or breast cancer risk, even among particular subgroups of 767 
women or for particular subtypes of disease, nor is it a marker of differential outcome following 768 
diagnosis with these cancers. Therefore, genetic test results for rs61764370 should not be used to 769 
counsel women about their ovarian or breast cancer risks or outcome. Our results highlight the 770 
dangers of developing clinical tests without appropriate data from carefully conducted, large-scale 771 
studies to establish clinical validity.  772 
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TABLE LEGENDS 1330 
Table 1.  Associations between KRAS rs61764370 and risk of ovarian and breast cancer. 1331 
For BRCA1 and BRCA2 mutation carrier analyses, cases are affected BRCA1/BRCA2 mutation 1332 
carriers and controls are unaffected BRCA1/BRCA2 mutation carriers, and relative risks are 1333 
estimated by hazard ratios; for other analyses, relative risks are estimated by odds ratios; ovarian 1334 
cancer analyses used OCAC data adjusted for study, age, and the five European principal 1335 
components; breast cancer analyses used BCAC data adjusted for study, age, and the seven 1336 
European principal components; BRCA1 and BRCA2 mutation carrier analyses used CIMBA data 1337 
with age as follow-up time and stratified for country; 95% CI, 95% confidence interval.  1338 
 1339 
Table 2.  Associations between KRAS rs61764370 and outcome in ovarian and breast 1340 
cancer. 1341 
Ovarian cancer analyses used OCAC data adjusted for age at diagnosis (overall survival only), the 1342 
five European principal components, histology (serous, mucinous, endometrioid, clear cell, and 1343 
other epithelial), grade (low versus high), FIGO stage (I-IV), residual disease after debulking 1344 
surgery (nil versus any), and stratified by study; breast cancer analyses used BCAC data adjusted 1345 
for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy and 1346 
was stratified by study; analyses for BRCA1 and BRCA2 mutation carriers used CIMBA data 1347 
adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or 1348 
chemotherapy, and preventive bilateral oophorectomy and was stratified by study; 95% CI, 95% 1349 
confidence interval.  1350 
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FIGURE LEGENDS 1351 
Figure 1. Regional association plots for variants within the genomic region 100 kb either 1352 
side of KRAS and risk of ovarian and breast cancer.  1353 
X-axis position is referent to position (bp) on chromosome 12, build GRCh37.p12; yellow line 1354 
indicates position of KRAS; red triangle indicates rs61764370. Y-axis is –log10(p-values) from 1355 
association tests for risk of A) ER-negative breast cancer, B) ER-positive breast cancer, C) Breast 1356 
cancer in BRCA1 mutation carriers, D) Breast cancer in BRCA2 mutation carriers, E) Epithelial 1357 
ovarian cancer, F) Epithelial ovarian cancer in BRCA1 mutation carriers, and G) Epithelial ovarian 1358 
cancer in BRCA2 mutation carriers. 1359 
 1360 
Figure 2. Power curve for modest risk variants according to the total sample size.  1361 
X-axis is total sample size for which case-control ratio is 1:1. Y- axis is the statistical power (range 1362 
0·5-1·0) for variants given a range of risks, assuming alpha=0·01 and minor allele frequency 0·09. 1363 
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ABSTRACT 519 
Objective. Clinical genetic testing is commercially available for rs61764370, an inherited 520 
variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with 521 
increased ovarian and breast cancer risk as well as with survival time. However, prior studies, 522 
emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated 523 
ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.  524 
Methods. Centralized genotyping and analysis was performed for 140,012 women enrolled 525 
in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), 526 
the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and 527 
the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7,904 BRCA2 mutation 528 
carriers).  529 
Results. We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94–1.04, 530 
p=0.74) or breast cancer (OR=0.98, 95% CI 0.94–1.01, p=0.19) and results were consistent 531 
among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97–1.23, p=0.14, breast 532 
cancer HR=1.04, 95% CI 0.97–1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71–1.13, 533 
p=0.34, breast cancer HR=1.06, 95% CI 0.94–1.19, p=0.35). Null results were also obtained for 534 
associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83–1.07, p=0.38), 535 
breast cancer (HR=0.96, 95% CI 0.87–1.06, p=0.38), and all other previously-reported 536 
associations.  537 
Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with 538 
clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical 539 
utility related to the prediction or management of these cancers.  540 
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INTRODUCTION 541 
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that negatively 542 
regulate gene expression by binding partially complementary sites in the 3′ untranslated regions 543 
(UTRs) of their target mRNAs. In this way, miRNAs control many cancer-related biological 544 
pathways involved in cell proliferation, differentiation, and apoptosis [1]. To date, several inherited 545 
variants in microRNAs or miRNA target sites have been reported to confer increased cancer risks 546 
[2]. One such variant is located in the 3′ UTR of the KRAS gene (rs61764370 T>G) for which the 547 
rarer G allele has been reported to confer an increased risk of ovarian, breast, and lung cancer [3-548 
7] as well as endometriosis [8], although not consistently [9-11].  549 
For ovarian cancer, the rs61764370 G allele was also reported to be associated with 550 
increased risk (320 cases, 328 controls). Further increased risks were observed among 23 BRCA1 551 
mutation carriers and 31 women with familial ovarian cancer, but without BRCA1 or BRCA2 552 
mutations [3]. In contrast, no association with ovarian cancer risk was seen in another, much larger 553 
study, based on 8,669 cases, 10,012 controls, and 2,682 BRCA1 mutation carriers [9]. One 554 
criticism on the latter study was that some of the genotype data were for rs17388148, an imputed 555 
proxy for rs61764370; even though rs17388148 is highly correlated with rs61764370 (r2=0.97) and 556 
was imputed with high accuracy (r2=0.977) [12, 13]. The minor allele of rs61764370 was also 557 
associated with shorter survival time in a study of 279 ovarian cancer patients diagnosed after age 558 
52 years with platinum-resistant disease (28 resistant, 263 not resistant) and with sub-optimal 559 
debulking surgery after neoadjuvant chemotherapy (7 sub-optimal, 109 optimal) [14]. However, 560 
another study observed no association between rs61764370 and  ovarian cancer outcome (329 561 
cases) [15].  562 
For breast cancer, a borderline significant increased frequency of the rs61764370 G allele 563 
was observed in 268 BRCA1 mutation carriers with breast cancer, but not in 127 estrogen receptor 564 
(ER)-negative familial non-BRCA1/BRCA2 breast cancer patients [5]. However, in a subsequent 565 
study, the variant was reported to be associated with increased risk of ER/PR negative disease (80 566 
cases, 470 controls), as well as with triple negative breast cancer diagnosed before age 52 (111 567 
cases, 250 controls), regardless of BRCA1 mutation status [6]. The validity of these findings has 568 
been questioned given the very small sample sizes and the number of subgroups tested [16, 17]. 569 
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Another report found no association with sporadic or familial breast cancer risk (695 combined 570 
cases, 270 controls), but found that the variant was associated with ERBB2-positive and high 571 
grade disease, based on 153 cases who used post-menopausal hormone replacement therapy 572 
[18].  573 
It has also been reported, based on 232 women with both primary ovarian and breast 574 
cancer, that the frequency of the G allele at rs61764370 was increased for those who were 575 
screened negative for BRCA1 and BRCA2 (92 cases), particularly among those enrolled within two 576 
years of their ovarian cancer diagnosis (to minimize survival bias, 30 cases), those diagnosed with 577 
post-menopausal ovarian cancer (63 cases), those with a family history of ovarian or breast cancer 578 
(24 cases), and those with a third primary cancer (16 cases) [4].  579 
This notable lack of consistency in findings between studies might be expected when 580 
appropriate levels of statistical significance are not used to declare positive findings from multiple 581 
small subgroup comparisons or post-hoc hypotheses [19]. In this respect, the dangers of subgroup 582 
analyses in the context of clinical trials are well-recognized [20]. These are important caveats, 583 
particularly since a genetic test for rs61764370 is currently marketed in the US for risk prediction 584 
testing to women who are at increased risk for developing ovarian and/or breast cancer or women 585 
who have been diagnosed with either ovarian or breast cancer themselves [21]. In general, much 586 
larger studies, with sufficient power to detect positive findings at much more stringent levels of 587 
statistical significance ought to be required to establish the clinical validity of a genetic test. 588 
Therefore, we conducted centralized genotyping of rs61764370 and other variants in the genomic 589 
region around the KRAS gene in 140,012 women to examine associations with risk and clinical 590 
outcome of ovarian and breast cancer.  591 
 592 
METHODS 593 
Study Participants  594 
The following three consortia contributed to these analyses: the Ovarian Cancer 595 
Association Consortium (OCAC: 41 studies, Supplementary Table S1) [22], the Breast Cancer 596 
Association Consortium (BCAC: 37 studies, Supplementary Table S2) [23], and the Consortium of 597 
Modifiers of BRCA1 and BRCA2 (CIMBA: 55 studies, Supplementary Table S3) [24, 25]. OCAC 598 
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and BCAC consisted of case-control studies of unrelated women, and CIMBA consisted of studies 599 
of women with germline deleterious BRCA1 or BRCA2 mutations primarily identified through 600 
clinical genetics centers. For the purpose of the current analyses, only participants of European 601 
ancestry were included. Following genotyping, quality control exclusions (described below), and 602 
analysis-specific exclusions, data from the following women were available for analysis: 46,173 603 
OCAC participants (15,357 patients with invasive epithelial ovarian cancer and 30,816 controls), 604 
71,170 BCAC participants (33,530 patients with invasive breast cancer and 37,640 controls), and 605 
22,669 CIMBA participants (for ovarian cancer analyses: 2,332 affected and 12,433 unaffected 606 
BRCA1 carriers, 599 affected and 7,305 unaffected BRCA2 carriers; for breast cancer analyses: 607 
7,543 affected and 7,222 unaffected BRCA1 carriers, 4,138 affected and 3,766 unaffected BRCA2 608 
carriers). For OCAC, overall and progression-free survival data were available for 3,096 patients 609 
from 13 studies. Overall survival data were available for 28,471 patients from 26 BCAC studies 610 
and for 2,623 mutation carriers with breast cancer from 11 CIMBA studies (excluding studies with 611 
less than ten deaths) as described previously [26, 27]. Each study was approved by its relevant 612 
governing research ethics committee, and all study participants provided written informed consent. 613 
 614 
Genotyping and Imputation  615 
Genotyping for rs61764370 was performed using the custom iCOGS Illumina Infinium 616 
iSelect BeadChip, as previously described [22-25]. In total, DNA from 185,443 women of varying 617 
ethnic background was genotyped (47,630 OCAC participants, 114,255 BCAC participants, 23,558 618 
CIMBA participants), along with HapMap2 DNAs for European, African, and Asian populations. 619 
Genotype data were also available for three OCAC genome-wide association studies (UK GWAS, 620 
US GWAS, Mayo GWAS) that had been genotyped using either the Illumina Human610-Quad 621 
Beadchip (12,607 participants) [28] or the Illumina HumanOmni2.5-8 Beadchip (883 participants). 622 
Raw intensity data files underwent centralized genotype calling and quality control [22-25]. 623 
HapMap2 samples were used to identify women with predicted European intercontinental ancestry; 624 
among these women, a set of over 37,000 unlinked markers was used to perform principal 625 
component (PC) analysis [29]. The first five and seven European PCs were found to control 626 
adequately for residual population stratification in OCAC and BCAC data, respectively. Samples 627 
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with low conversion rate, extreme heterozygosity, non-female sex, or one of a first-degree relative 628 
pair (the latter for OCAC and BCAC only) were excluded. Variants were excluded if they were 629 
monomorphic or had a call rate <95% (minor allele frequency (MAF) >0.05) or <99% (MAF <0.05), 630 
deviation from Hardy-Weinberg equilibrium (p <10-7), or >2% duplicate discordance.  631 
In addition to rs61764370, 54 variants within 100 kb on either side of KRAS on 632 
chromosome 12 (25,258,179 to 25,503,854 bp in GRCh37.p12) were genotyped. Moreover, to 633 
provide a common set of variants across the region for analysis in all the data sets, we also used 634 
imputation to infer genotypes for another 1,056 variants and for variants that failed genotyping.  635 
We performed imputation separately for OCAC samples, BCAC samples, BRCA1 mutation 636 
carriers, BRCA2 mutation carriers, and for each of the OCAC GWAS. We imputed variants from 637 
the 1000 Genomes Project data using the v3 April 2012 release as the reference panel [30]. To 638 
improve computation efficiency we initially used a two-step procedure, which involved pre-phasing 639 
using the SHAPEIT software [31] in the first step and imputation of the phased data in the second. 640 
We used the IMPUTE version 2 software [32] for the imputation for all studies with the exception of 641 
the US GWAS for which we used the MACH algorithm implemented in the minimac software 642 
version 2012.8.15 and MACH version 1.0.18 [33]. We excluded variants from association analyses 643 
if their imputation accuracy was r2<0.30 or their MAF was <0.005, resulting in 974 variants 644 
genotyped and imputed for OCAC, 989 variants genotyped and imputed for BCAC, and 1,001 645 
variants genotyped and imputed for CIMBA, including rs61764370 (Supplementary Tables S5, S6, 646 
and S7).  647 
 648 
Analysis   649 
Genotypes were coded for genotype dosage as 0, 1, or 2, based on the number of copies 650 
of the minor allele. For ovarian cancer case-control analysis (i.e., OCAC studies), logistic 651 
regression provided estimated risks of invasive epithelial ovarian cancer with odds ratios (ORs) 652 
and 95% confidence intervals (CIs) adjusting for study, age, and the five European PCs. Subgroup 653 
analyses were conducted by histology, family ovarian and breast cancer history, menopausal 654 
status, time between ovarian cancer diagnosis and recruitment, and history of multiple primary 655 
cancers. For breast cancer case-control analysis (i.e., BCAC studies), the association between 656 
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genotype and invasive breast cancer risk was evaluated by logistic regression, adjusting for study, 657 
age, and the seven European PCs, providing ORs and 95% CIs. Additional subgroup analyses 658 
were based on receptor status, first-degree family ovarian and breast cancer history, BRCA1 and 659 
BRCA2 mutation status, enrollment within two years of diagnosis, menopausal status (i.e. last 660 
menstruation longer than twelve months ago), age at diagnosis less than 52 years, and history of 661 
hormone replacement therapy use (i.e. longer than twelve months use). Risk analysis for BRCA1 662 
and BRCA2 mutation carriers (i.e. CIMBA studies) was done using a Cox proportional hazard 663 
model to estimate hazard ratios (HRs) per copy of the minor allele, with age as follow-up time and 664 
stratified by country of residence; US and Canadian strata were further subdivided by self-reported 665 
Ashkenazi Jewish ancestry [24, 25]. A weighted cohort approach was applied to correct for 666 
potential testing bias due to overrepresentation of cases in the study population [34]. We used 667 
robust variance estimation to allow for the non-independence of carriers within the same family 668 
[35]. To assess associations with ovarian cancer risk, mutation carriers were followed from birth 669 
until ovarian cancer diagnosis (event), a risk-reducing salpingo-oophorectomy (RRSO) or the age 670 
at enrollment, whichever occurred first. We also performed analyses restricted to women 671 
diagnosed or censored within two years before their enrollment. To assess associations with 672 
breast cancer risk, mutation carriers were followed from birth until a breast cancer diagnosis (i.e. 673 
either ductal carcinoma in situ or invasive breast cancer), ovarian cancer diagnosis, a risk-reducing 674 
bilateral prophylactic mastectomy or the age at enrollment, whichever occurred first. 675 
Survival analysis of OCAC patients used Cox proportional hazards models estimating HRs 676 
and 95% CIs considering overall survival as well as progression-free survival following ovarian 677 
cancer diagnosis. Overall survival was adjusted for age at diagnosis, the five European PCs, 678 
histology, grade, FIGO stage, residual disease after debulking surgery, and stratified by study, left 679 
truncating at the date of study entry and right censoring at five years to minimize events due to 680 
other causes. Progression-free survival was analyzed as for overall survival, but without 681 
adjustment for age and right censoring, and was defined as the time between the date of histologic 682 
diagnosis and the first confirmed sign of disease recurrence or progression, based on GCIG 683 
(Gynecological Cancer InterGroup) criteria [36]. We also performed subgroup analysis of patients 684 
suboptimally debulked after cytoreductive surgery (residual disease >1cm) and of post-685 
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menopausal patients (age at diagnosis >52 years). Survival analysis of BCAC patients used Cox 686 
proportional hazard models estimating HRs and 95% CIs considering overall and breast cancer-687 
specific survival following breast cancer diagnosis. Models were adjusted for age at diagnosis, 688 
tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy, and stratified by study, 689 
left-truncating at the date of study entry and right censoring at ten years. In addition, we performed 690 
subgroup analysis on ER-positive and ER-negative patients. For CIMBA breast cancer patients 691 
associations between genotype and overall survival were evaluated using Cox proportional hazard 692 
models estimating HRs and 95% CIs. Models were adjusted for age at diagnosis, tumor size, nodal 693 
status, grade, adjuvant hormonal and/or chemotherapy, and preventive bilateral oophorectomy and 694 
stratified by study, left-truncating at the date of study entry and right censoring at twenty years. 695 
Analyses were performed using STATA version 12.0 (StataCorp, Texas, USA).  696 
 697 
RESULTS 698 
The results of the overall analysis as well as the subgroup analyses investigating the 699 
association between the minor allele at rs61764370 and ovarian cancer risk, breast cancer risk, 700 
and ovarian and breast cancer risks in BRCA1 and BRCA2 mutation carriers are shown in Table 1. 701 
Associations with clinical outcomes in and ovarian and breast cancer patients including BRCA1 702 
and BRCA2 mutation carriers are shown in Table 2 and Supplementary Table S4.  703 
We found no evidence for association between the rs61764370 G allele and ovarian or 704 
breast cancer risk. The most statistically significant association was observed for risk of low-grade 705 
serous ovarian cancer (n=485; OR 0.76, 95% CI 0.59-0.97, p=0.031), but this finding was not 706 
significant after Bonferroni correction for multiple testing. We also evaluated the association for 707 
additional specific subgroups in which an association with rs61764370 had been reported 708 
previously [3-6]. Ovarian cancer subgroups considered BRCA1 mutation carriers as well as 709 
BRCA1 and BRCA2 screened-negative patients with first degree family histories of breast or 710 
ovarian cancer and patients who had been diagnosed with breast cancer before their ovarian 711 
cancer diagnoses. For breast cancer these included, amongst others, BRCA1 mutation carriers, 712 
patients diagnosed with ER- and PR-negative tumors, and patients diagnosed with triple negative 713 
tumors before age 52 years. Importantly, we observed no evidence for association of rs61764370 714 
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with any of these subgroups (detailed in Table 1), with all ORs close to unity and very narrow CIs 715 
including unity. 716 
Similarly, case-only analyses did not reveal any associations between rs61764370 717 
genotype and ovarian and breast cancer clinical features or outcome (Table 2 and Supplementary 718 
Table S4). For example, the previously reported association between rs61764370 and risk of 719 
ERBB2-positive and high grade breast cancer in hormone replacement therapy users [18] was not 720 
replicated (Supplementary Table S4), and in ovarian cancer analyses we found no evidence of 721 
reduced survival among patients diagnosed after age 52 years or patients with suboptimal 722 
debulking after cytoreductive surgery (Table 2) [14]. The G allele of rs61764370 was also not 723 
associated with survival of breast cancer patients (Table 2). 724 
Finally, we evaluated the association between the primary phenotypes of interest and 725 
common genetic variation (MAF>0.02) in the genomic region of KRAS (i.e., within 100 kb on either 726 
side of the gene), using imputed and genotyped data on 974 variants for OCAC, 989 variants for 727 
BCAC, and 1,001 variants genotyped and imputed for CIMBA (Supplementary Tables S5, S6, and 728 
S7). We found no evidence of association for any of these variants, including rs61764370 and 729 
rs17388148, with these phenotypes that would withstand Bonferroni correction for multiple testing, 730 
as detailed in Supplementary Tables S5, S6, and S7 and shown in regional association plots 731 
(Figure 1). 732 
 733 
DISCUSSION 734 
Our analysis of 140,012 women genotyped for inherited variants in the KRAS region 735 
provides definitive clarification of the role of these variants in ovarian and breast cancer 736 
susceptibility and outcome.  We have found no evidence to support an association between 737 
rs61764370 and ovarian or breast cancer risk, or clinical outcomes in patients with ovarian or 738 
breast cancer. In the absence of any association and with ORs close to unity we would not 739 
typically consider sub-group analyses, particularly sub-groups for which differential associations 740 
would not be expected to occur. However, given the previous positive associations reported for a 741 
myriad of different subgroups, we tested for association among each of these subgroups and 742 
found no evidence to support the previously reported associations.   743 
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Our study has notable strengths. The vast majority (i.e. >95%) of the samples were 744 
genotyped using the same genotyping platform and employing a common approach to genotype 745 
calling and quality control; additional samples used denser arrays and nearly identical procedures. 746 
The very large sample sizes for all the major phenotypes of interest provide substantial statistical 747 
power to exclude any clinically relevant associated risks for the major phenotypes of interest 748 
(Figure 2). The null results found here are thus not due to lack of statistical power, and this 749 
analysis also had greater than 80% power to detect association for most of the subgroups, 750 
although for some subgroups it was not possible to exclude modest risks. In contrast to the current 751 
findings, other genetic association analyses using the same genotyping platform and the same 752 
studies as included here have identified more than 90 common germline variants associated with 753 
ovarian or breast cancer risk at p< 5 x 10-8 [22, 23, 37]. While critiques on a previous null KRAS 754 
report have suggested that inclusion of male controls, use of “prevalent” cases, and reliance on a 755 
surrogate genetic variant may have led to falsely negative conclusions, these are not issues in the 756 
present data set. Rather, we demonstrate the importance of international collaboration to identify 757 
true associations as well as to refute false associations, an equally important objective. 758 
The rise of individualized medicine including the use of panels of common variants to 759 
predict cancer risk more accurately than using family history alone holds great promise [38]. For 760 
example, the 31 prostate cancer susceptibility alleles confirmed as of 2011 (at p<5x10-8) can be 761 
combined to identify men in the top one percent of the risk distribution having a 3.2-fold increased 762 
risk [39]. Prediction has since then improved with now over 70 prostate cancer susceptibility alleles 763 
[40] and the utility of these genetic tests is currently under clinical evaluation. Similar clinical 764 
examination in ovarian and breast cancer is not far behind, with now over 18 and 77 confirmed 765 
susceptibility alleles (at p<5x10-8), respectively, for these cancers [22, 23]. The genotype at 766 
rs61764370, however, does not predict ovarian or breast cancer risk, even among particular 767 
subgroups of women or for particular subtypes of disease, nor is it a marker of differential outcome 768 
following diagnosis with these cancers. Therefore, genetic test results for rs61764370 should not 769 
be used to counsel women about their ovarian or breast cancer risks or outcome. Our results 770 
highlight the dangers of developing clinical tests without appropriate data from carefully conducted, 771 
large-scale studies to establish clinical validity.  772 
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TABLE LEGENDS 1330 
Table 1.  Associations between KRAS rs61764370 and risk of ovarian and breast cancer. 1331 
For BRCA1 and BRCA2 mutation carrier analyses, cases are affected BRCA1/BRCA2 mutation 1332 
carriers and controls are unaffected BRCA1/BRCA2 mutation carriers, and relative risks are 1333 
estimated by hazard ratios; for other analyses, relative risks are estimated by odds ratios; ovarian 1334 
cancer analyses used OCAC data adjusted for study, age, and the five European principal 1335 
components; breast cancer analyses used BCAC data adjusted for study, age, and the seven 1336 
European principal components; BRCA1 and BRCA2 mutation carrier analyses used CIMBA data 1337 
with age as follow-up time and stratified for country; 95% CI, 95% confidence interval.  1338 
 1339 
Table 2.  Associations between KRAS rs61764370 and outcome in ovarian and breast 1340 
cancer. 1341 
Ovarian cancer analyses used OCAC data adjusted for age at diagnosis (overall survival only), the 1342 
five European principal components, histology (serous, mucinous, endometrioid, clear cell, and 1343 
other epithelial), grade (low versus high), FIGO stage (I-IV), residual disease after debulking 1344 
surgery (nil versus any), and stratified by study; breast cancer analyses used BCAC data adjusted 1345 
for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy and 1346 
was stratified by study; analyses for BRCA1 and BRCA2 mutation carriers used CIMBA data 1347 
adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or 1348 
chemotherapy, and preventive bilateral oophorectomy and was stratified by study; 95% CI, 95% 1349 
confidence interval.  1350 
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FIGURE LEGENDS 1351 
Figure 1. Regional association plots for variants within the genomic region 100 kb either 1352 
side of KRAS and risk of ovarian and breast cancer.  1353 
X-axis position is referent to position (bp) on chromosome 12, build GRCh37.p12; yellow line 1354 
indicates position of KRAS; red triangle indicates rs61764370. Y-axis is –log10(p-values) from 1355 
association tests for risk of A) ER-negative breast cancer, B) ER-positive breast cancer, C) Breast 1356 
cancer in BRCA1 mutation carriers, D) Breast cancer in BRCA2 mutation carriers, E) Epithelial 1357 
ovarian cancer, F) Epithelial ovarian cancer in BRCA1 mutation carriers, and G) Epithelial ovarian 1358 
cancer in BRCA2 mutation carriers. 1359 
 1360 
Figure 2. Power curve for modest risk variants according to the total sample size.  1361 
X-axis is total sample size for which case-control ratio is 1:1. Y- axis is the statistical power (range 1362 
0·5-1·0) for variants given a range of risks, assuming alpha=0·01 and minor allele frequency 0·09. 1363 
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 Number 
Minor allele 
frequency 
 
Relative Risk  
(95% CI) 
 
 Cases Controls Cases Controls P-value 
Ovarian Cancer 
     
  
All invasive 15,357 30,816 0.0914 0.0949 0.99 (0.94-1.04) 0.74 
Histology 
      
High-grade serous 6,938 30,816 0.0946 0.0949 1.04 (0.97-1.11) 0.26 
Endometrioid 2,151 30,816 0.0834 0.0949 0.90 (0.80-1.00) 0.06 
Clear cell 1,015 30,816 0.0994 0.0949 1.09 (0.94-1.27) 0.27 
Mucinous 1,000 30,816 0.0902 0.0949 0.99 (0.85-1.16) 0.91 
Low-grade serous 485 30,816 0.0705 0.0949 0.76 (0.59-0.97) 0.03 
First-degree family history  
      
Ovarian cancer 483 342 0.0803 0.0849 0.87 (0.60-1.27) 0.47 
Breast or ovarian cancer 477 18,442 0.0977 0.0915 1.09 (0.93-1.28) 0.28 
    BRCA1/2 mutation negative 346 15,492 0.1050 0.0997 1.09 (0.85-1.41) 0.49 
BRCA1 mutation carriers 2,332 12,433 0.0954 0.0922 1.09 (0.97-1.23) 0.14 
BRCA2 mutation carriers 599 7,305 0.0952 0.0966 0.89 (0.71-1.13) 0.34 
Enrolled within two years of 
diagnosis 
      
    All invasive 10,121 30,815 0.0942 0.0949 0.99 (0.95-1.04) 0.68 
    BRCA1 mutation carriers 1,095 10,802 0.0950 0.0940 1.05 (0.90-1.23) 0.52 
    BRCA2 mutation carriers 270 6,509 0.0907 0.0979 0.85 (0.60-1.20) 0.36 
Menopausal Status       
    Pre- or peri-menopausal 4,264 8,789 0.0915 0.0927 1.02 (0.92-1.13) 0.68 
    Post-menopausal 11,058 15,903 0.0916 0.0951 0.99 (0.93-1.06) 0.81 
Prior breast cancer       
    Enrolled within two years of 
    diagnosis 
426 30,815 0.0943 0.0949 0.91 (0.71-1.17) 0.46 
    Post-menopausal ovarian      
    cancer  
341 15,903 0.0810 0.0951 0.90 (0.68-1.21) 0.49 
    First degree breast or ovarian  
    cancer family history 
202 30,815 0.0916 0.0949 0.99 (0.70-1.40) 0.95 
Breast Cancer           
All invasive 33,530 37,640 0.0904 0.0930 0.98 (0.94-1.01) 0.19 
Receptor status       
    ER-/PR- 4,009 37,043 0.0940 0.0932 1.04 (0.96-1.13) 0.36 
    ER-/PR-/ERBB2- 1,673 28,480 0.0885 0.0947 0.97 (0.85-1.10) 0.62 
First-degree family history        
    Breast cancer 4,357 1,943 0.0942 0.0954 0.96 (0.84-1.10) 0.59 
    Ovarian or breast cancer 4,593 2,265 0.0933 0.0949 0.96 (0.85-1.09) 0.52 
Age diagnosis <52       
    ER-/PR- 1,530 37,043 0.0980 0.0932 1.07 (0.95-1.22) 0.28 
    ER-/PR-/ERBB2- 546 27,690 0.0908 0.0948 0.99 (0.81-1.20) 0.90 
BRCA1/2 mutation negative 1,431 1,097 0.0853 0.0925 0.91(0.75-1.11) 0.35 
BRCA1 mutation carriers 7,543 7,222 0.0935 0.0919 1.04 (0.97-1.12) 0.27 
BRCA2 mutation carriers 4,138 3,766 0.1005 0.0921 1.06 (0.94-1.19) 0.35 
Enrolled within two years of 
diagnosis 
      
    All invasive 20,444 34,349 0.0924 0.0934 0.99 (0.95-1.04) 0.73 
    BRCA1 mutation carriers 2,595 5,976 0.0896 0.0924 0.95 (0.85-1.05) 0.30 
    BRCA2 mutation carriers 1,359 3,365 0.0960 0.0926 1.05 (0.90-1.23) 0.52 
Menopausal atatus       
    Pre- or peri-menopausal                              7,086 8,642 0.0934 0.0933 0.98 (0.91-1.07) 0.70 
    Post-menopausal 16,346 18,605 0.0904 0.0943 0.98 (0.93-1.03) 0.36 
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N Patients N Events 
Hazard Ratio 
(95% CI) 
P-value 
Ovarian Cancer         
Overall survival     
   All patients 3,096 1,421 0.94 (0.83-1.07) 0.38 
   Patients who were suboptimally debulked after 
cytoreductive surgery 
1,114 784 0.94 (0.78-1.13) 0.50 
   Post-menopausal patients > 52 years 2,226 1,276 0.97 (0.84-1.12) 0.70 
Progression-free survival  
   
   All patients 3,096 2,144 1.01 (0.90-1.13) 0.84 
   Patients who were suboptimally debulked after 
cytoreductive surgery 
1,114 961 1.03 (0.87-1.21) 0.74 
   Post-menopausal patients > 52 years 2,226 1,603 1.02 (0.90-1.16) 0.76 
Breast Cancer         
Overall survival      
   All patients 28,471 3,013 0.96 (0.87-1.06) 0.38 
   ER-positive patients  20,071 1,754 0.96 (0.85-1.10) 0.58 
   ER-negative patients 4,778 771 0.97 (0.81-1.18) 0.78 
Breast cancer-specific survival     
   All patients 28,471 1,693 0.95 (0.83-1.08) 0.40 
Overall survival     
   BRCA1 mutation carriers 1,706 241 0.72 (0.48-1.08) 0.11 
   BRCA2 mutation carriers 917 162 0.98 (0.65-1.46) 0.90 
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Supplementary Table S1.  Participating Ovarian Cancer Association Consortium (OCAC) Studies 
OCAC Study Name Abbreviation Study Location Study Type Controls Cases (with 
survival) 
Australian Ovarian Cancer Study/Australian Cancer 
Study (Ovarian Cancer) 
AUS Australia  Population based/ case-
control 
977 880  (678) 
Bavarian Ovarian Cancer Cases and Controls BAV Southeast Germany  Population based/ case-
control 
143 93  (90) 
Belgian Ovarian Cancer Study BEL Belgium, University Hospital Leuven Hospital based/ case-control 1,349 275  (236) 
Diseases of the Ovary and their Evaluation DOV USA: 13 counties in western Washington 
state 
Population based/ case-
control 
1,487 904 (0) 
Oregon Ovarian Cancer Registry ORE USA: Portland, Oregon  Case only 0 55 (49) 
German Ovarian Cancer Study GER Germany: two geographical regions in the 
states of Baden-Württemberg and 
Rhineland-Palatinate in southern Germany 
Population based/ case-
control 
413 189 (0) 
Dr. Horst Schmidt Kliniken HSK Germany  Case only  144 (144) 
Hawaii Ovarian Cancer Case-Control Study HAW USA: Hawaii Population based/ case-
control 
157 60 (51) 
Hannover-Jena Ovarian Cancer Study HJO Germany  Hospital based/ case-control 273 266 (0) 
Hannover-Minsk Ovarian Cancer Study HMO Belarus  Case-control 138 143 (0) 
Helsinki Ovarian Cancer Study HOC Helsinki, Finland  Case-control 447 221 (0) 
Novel Risk Factors and Potential Early Detection 
Markers for Ovarian Cancer 
HOP USA: Western PA, Northeastern Ohio, 
Western New York 
Population based/ case-
control 
1,464 654 (0) 
Gilda Radner Familial Ovarian Cancer Registry  GRR USA: National Familial cancer/ case only  132 (0) 
Women’s Cancer Program at the Samuel Oschin 
Comprehensive Cancer Institute 
LAX USA: Southern California Case only  277 (222) 
Los Angeles County Case-control studies of Ovarian 
Cancer-1 
USC USA: Los Angeles County, California  Population based/ case-
control 
1047 689 (0) 
MALignant OVArian Cancer MAL Denmark  Population based/ case-
control 
828 440 (363) 
Danish Pelvic Mass Study PVD Denmark  Case only 0 169 (152) 
Mayo Clinic Ovarian Cancer Case-Control Study MAY USA: North Central (MN, SD, ND, IL, IA, 
WI) 
Clinic based/ case-control 971 811 (687) 
Melbourne Collaborative Cohort Study MCC Melbourne, Australia  Cohort/ Nested case-control 66 63 (0) 
MD Anderson Ovarian Cancer Study MDA USA: Texas Hospital based/ Case-
control 
384 373 (0) 
Memorial Sloan-Kettering Cancer Center  MSK USA: New York City Case-control 593 467 (0) 
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OCAC Study Name Abbreviation Study Location Study Type Controls Cases (with 
survival) 
North Carolina Ovarian Cancer Study NCO USA: Central and eastern North Carolina 
(48 counties) 
Population based/ case-
control 
826 761 (213) 
New England Case Control Study NEC USA: New Hampshire and Eastern 
Massachusetts 
Population based/ case-
control 
1,122 766 (87) 
Nurses’ Health Study NHS USA: National  Population based/ Nested 
case-control 
455 138 (0) 
New Jersey Ovarian Cancer Study NJO USA: New Jersey (six counties) Case-control 181 169 (0) 
University of Bergen, Haukeland University Hospital, 
Norway 
NOR Norway  Case-control 371 237 (0) 
Nijmegen Ovarian Cancer Study NTH Eastern part of the Netherlands Case-control 323 255 (0) 
Ovarian Cancer in Alberta and British Columbia OVA Alberta and British Columbia, Canada Case-control 748 631 (0) 
Polish Ovarian Cancer Study POC Poland: Szczecin, Poznan, Opole, 
Rzeszów 
Case-control 417 422 (0) 
Polish Ovarian Cancer Case Control Study POL Poland: Warsaw, and Lodz Population based/ case-
control 
741 260 (0) 
Study of Epidemiology and Risk Factors in Cancer 
Heredity 
SEA UK: East Anglia and West Midlands Population based/ case-
control 
6,024 1,385 (0) 
Family Registry for Ovarian Cancer and Genetic 
Epidemiology of Ovarian Cancer 
STA USA: Six counties in the San Francisco 
Bay area 
Population based/ case-
control 
313 251 (0) 
Tampa Bay Ovarian Cancer Study TBO USA: Florida Case-control 169 227 (0) 
Toronto Ovarian Cancer Study TOR Canada: Province of Ontario Population based 598 755 (0) 
University of California Irvine Ovarian Study UCI USA: Southern California (Orange and 
San-Diego, Imperial Counties) 
Population based/ case-
control 
367 277 (0) 
United Kingdom Ovarian Cancer Population Study UKO UK: England, Wales and Northern Ireland Population based/ case-
control 
1,104 730 (0) 
Royal Marsden Hospital Ovarian Cancer Study RMH UK: London Hospital based/ case only 0 154 (0) 
UK Familial Ovarian Cancer Registry UKR UK: National Case only/ familial register 0 47 (0) 
Southampton Ovarian Cancer Study SOC UK: Wessex region Case only/ hospital based 0 267 (0) 
Scottish Randomised Trial in Ovarian Cancer SRO UK: coordinated through clinical trials unit, 
Glasgow UK from patients recruited world-
wide 
Case only/ clinical trial 0 158 (124) 
Warsaw Ovarian Cancer Study  WOC Poland: Warsaw and central Poland Case-control 204 202  (0) 
TOTAL    30,816 15,397 (3,096) 
 
Totals represent the number of subjects passing quality control criteria included in these analyses; number in parentheses is number with survival time data. 
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Supplementary Table S2.  Participating Breast Cancer Association Consortium (BCAC) Studies 
BCAC Study Name Abbreviation Study Location Study Type Controls Cases (with 
survival) 
Australian Breast Cancer Family Study ABCFS Australia: Melbourne and Sydney Population based/ 
case-control 
490 720 (745) 
Amsterdam Breast Cancer Study ABCS The Netherlands, NKI-AVL Early onset & 
familial cancer/ 
mixed case-control 
1,156 1,069 (564) 
Bavarian Breast Cancer Cases and Controls BBCC Germany: Northern Bavaria Mixed/ case-control 457 553 (214) 
British Breast Cancer Study BBCS UK: England and Scotland Mixed/ case-control 1,302 1,408 (0) 
Breast Cancer in Galway Genetic Study BIGGS Western part of Ireland Hospital based/ 
case-control 
49 230 (0) 
Breast Cancer Study of the University Clinic Heidelberg BSUCH Germany: Heidelberg and Mannheim Hospital based/ 
case-control 
945 799 (384) 
CECILE Breast Cancer Study CECILE France: departments of Ille-et-Vilaine 
and Côte d’Or 
Mixed/ case-control 991 892 (0) 
Copenhagen General Population Study CGPS Denmark: Copenhagen Hospital based/ 
case-control 
3,927 2,269 (1,999) 
California Teachers Study CTS USA: California Cohort/ nested 
case-control 
44 51 (0) 
ESTHER Breast Cancer Study ESTHER Germany: Saarland Hospital based/ 
case-control 
500 465 (363) 
Gene Environment Interaction and Breast Cancer in Germany GENICA Germany: greater Bonn area Population based/ 
case-control 
420 463 (0) 
Helsinki Breast Cancer Study HEBCS Southern part of Finland Mixed/ case-control 1,226 600 (1428) 
Hannover-Minsk Breast Cancer Study HMBCS Belarus: Minsk, Gomel, Mogilev, 
Grodno, Brest and Vitebsk 
Mixed/ case-control 130 641 (0) 
Karolinska Breast Cancer Study KARBAC Sweden: Stockholm Familial cancer/ 
mixed case-control 
0 0 (402) 
Kuopio Breast Cancer Project KBCP Finland, Kuopio University Hospital Hospital based/ 
case-control 
250 407 (396) 
Kathleen Cuningham Foundation Consortium for Research 
into Familial Breast Cancer/Australian Ovarian Cancer Study 
kConFab/AOCS Australia and New Zealand Familial cancer/ 
mixed case-control 
867 357 (214) 
Leuven Multidisciplinary Breast Centre LMBC Belgium: Leuven Mixed/ case-control 1,386 2,484 (2,407) 
Mammary Carcinoma Risk Factor Investigation MARIE Germany: Hamburg and Rhein-
Neckar- Karlsruhe 
Population based/ 
case-control 
1,745 1,629 (1,577) 
Milan Breast Cancer Study Group MBCSG Italy:Milan Familial cancer/ 
mixed case-control 
389 189 (152) 
Page 4 of 8 
 
BCAC Study Name Abbreviation Study Location Study Type Controls Cases (with 
survival) 
Mayo Clinic Breast Cancer Study MCBCS USA: North Central (MN, SD, ND, IL, 
IA, WI) 
Mixed/ case-control 1,917 1,532 (1,368) 
Melbourne Collaborative Cohort Study MCCS Australia: Melbourne Prospective cohort 506 614 (508) 
Multiethnic Cohort MEC USA: California and Hawai  Prospective cohort 741 705 (644) 
Montreal Gene-Environment Breast Cancer study MTLGEBCS Canada: Montreal Mixed/ case-control 359 408 (0) 
Norwegian Breast Cancer Study NBCS Norway: Oslo, Bergen and Tromsø Mixed/ case-control 70 22 (0) 
Nashville Breast Health Study NBHS USA: Nashville Mixed/ case-control 119 122 (0) 
Oulu Breast Cancer Study OBCS Northern part of Finland Mixed/ case-control 410 500 (474) 
Ontario Familial Breast Cancer Registry OFBCR Canada: Ontario Population based/ 
case-control 
488 820 (925) 
Leiden University Medical Centre Breast Cancer Study ORIGO The Netherlands: South-West area Hospital based/ 
case-control 
0 0 (307) 
Polish Breast Cancer Study PBCS Poland Population based/ 
case-control 
423 519 (436) 
Karolinska Mammography Project for Risk Prediction of 
Breast Cancer 
pKARMA Sweden: Stockholm/Gotland area Population based/ 
case-control 
5,450 4,196 (4,403) 
Rotterdam Breast cancer Study RBCS The Netherlands: Rotterdam area Familial cancer/ 
mixed case-control 
0 0 (541) 
Singapore and Sweden Breast Cancer Study SASBAC Sweden Population based/ 
case-control 
1,268 1,150 (1,131) 
Sheffield Breast Cancer Study SBCS UK, Sheffield Mixed/ case-control 839 748 (674) 
Study of Epidemiology and Risk Factors in Cancer Hereditary SEARCH Eastern part of UK Mixed/ case-control 8,000 6,357 (6,097) 
Städtisches Klinikum Karlsruhe Deutsches  
Krebsforschungszentrum Study 
SKKDKFZS Germany: Karlsruhe Mixed/ case-control 0 0 (118) 
Szczecin Breast Cancer Study SZBCS Poland: West-Pomerania Mixed/ case-control 315 205 (0) 
Breakthrough Generations Study UKBGS UK Cohort/ nested 
case-control 
461 406 (0) 
TOTAL     37,640 33,530 (28,471) 
 
Totals represent the number of subjects passing quality control criteria included in these analyses; studies with zero cases other than those with survival data were excluded from 
case-control comparison, but included in survival analyses; number in parentheses is number with survival time data. 
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Supplementary Table S3. Participating Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) Studies 
CIMBA Study Name Abbreviation Study Location N Unaffected 
BRCA1 carriers:  
BC / OC 
N Affected BRCA1 
carriers: BC (with 
survival) / OC 
N Unaffected 
BRCA2 carriers: 
BC / OC 
N Affected BRCA2 
carriers: BC (with 
survival) / OC 
Breast Cancer Family Registry BCFR Australia, 
Canada, USA 
176 / 413 285 (80) / 48 152 / 330 196 (56) / 18 
Baltic Familial Breast Ovarian Cancer 
Consortium 
BFBOCC Lithuania 88 / 86 58 (0) / 60 0 / 0 0 (0) / 0 
Beth Israel Deaconess Medical Center BIDMC USA 18 / 41 27 (0) / 4 5 / 9 4 (0) / 0 
BRCA-gene mutations and breast 
cancer in South African women 
BMBSA South Africa 23 / 48 38 (0) / 13 53 / 132 93 (0) / 14 
Beckman Research Institute of the City 
of Hope 
BRICOH USA 114 / 154 62 (0) / 22 80 / 120 48 (0) / 8 
Copenhagen Breast Cancer Study CBCS Denmark 175 / 237 121 (0) / 59 49 / 86 45 (0) / 8 
Spanish National Cancer Centre Breast 
Cancer Study 
CNIO Spain 53 / 97 61 (0) / 17 113 / 211 113 (0) / 15 
City of Hope Cancer Center COH USA 86 / 202 139 (0) / 23 42 / 107 65 (0) / 0 
CONsortio Studi ITaliani sui Tumori 
Ereditari Alla Mammella 
CONSIT TEAM Italy 220 / 348 247 (0) / 119 65 / 163 117 (0) / 19 
National Center for Scientific Research 
“Demokritos” 
DEMOKRITOS Greece 73 / 142 121 (0) / 52 0 / 0 0 (0) / 0 
Dana Farber Cancer Institute DFCI USA 79 / 138 77 (0) / 18 79 / 130 55 (0) / 4 
German Cancer Research Center DKFZ Germany 18 / 58 41 (0) / 1 11 / 22 14 (0) / 3 
Epidemiological study of BRCA1 & 
BRCA2 mutation carriers 
EMBRACE UK 726 / 1,249 724 (544) / 201 545 / 946 475 (311) / 74 
Fox Chase Cancer Center FCCC USA 68 / 93 47 (0) / 22 35 / 45 19 (0) / 9 
German Consortium of Hereditary 
Breast and Ovarian Cancer 
GC-HBOC Germany 334 / 828 645 (0) / 151 185 / 492 348 (0) / 41 
Genetic modifiers of Cancer Risk in 
BRCA1/2 Mutation Carriers 
GEMO France 576 / 1,099 790 (0) / 267 204 / 653 502 (0) / 53 
Georgetown Hospital GEORGETOWN USA 6 / 16 10 (0) / 0 0 / 0 0 (0) / 0 
Ghent University Hospital G-FAST Belgium 121 / 237 149 (0) / 33 0 / 0 0 (0) / 0 
Gynecologic Oncology Group GOG USA 172 / 344 172 (0) / 0 159 / 306 147 (0) / 0 
Hospital Clinico San Carlos HCSC Spain 74 / 106 56 (0) / 24 54 / 104 59 (0) / 9 
Helsinki Breast Cancer Study HEBCS Finland 42 / 75 55 (50) / 22 55 / 110 66 (58) / 11 
Hereditary Breast and Ovarian Cancer HEBON Netherlands 687 / 1,113 564 (153) / 138 491 / 700 260 (45) / 51 
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CIMBA Study Name Abbreviation Study Location N Unaffected 
BRCA1 carriers:  
BC / OC 
N Affected BRCA1 
carriers: BC (with 
survival) / OC 
N Unaffected 
BRCA2 carriers: 
BC / OC 
N Affected BRCA2 
carriers: BC (with 
survival) / OC 
Research Group Netherlands  
Molecular Genetic Studies of Breast 
and Ovarian Cancer in Hungary 
HUNBOCS Hungary 60 / 120 83 (0) / 23 0 / 0 0 (0) / 0 
University Hospital Vall d’Hebron HVH Spain 25 / 48 33 (0) / 10 25 / 55 34 (0) / 4 
Institut Català d’Oncologica ICO Spain 113 / 170 99 (0) / 42 102 / 199 121 (0) / 24 
International Hereditary Cancer Centre IHCC Poland 392 / 652 311 (0) / 51 0 / 0 0 (0) / 0 
Iceland Landspitali-University Hospital ILUH Iceland 0 / 0 0 (0) / 0 25 / 122 101 (52) / 4 
Interdisciplinary Health Research 
International Team Breast Cancer 
susceptibility 
INHERIT Canada 54 / 83 42 (0) / 13 23 / 47 26 (0) / 2 
Istituto Oncologico Veneto IOVHBOCS Italy 59 / 75 72 (0) / 56 36 / 107 90 (0) / 19 
Portuguese Oncology Institute-Porto 
Breast Cancer Study 
IPOBCS Portugal 60 / 77 35 (0) / 18 0 / 0 0 (0) / 0 
Kathleen Cuningham Consortium for 
Research into Familial Breast Cancer 
KCONFAB Australia 312 / 654 418 (336) / 76 175 / 402 250 (192) / 23 
Modifiers and Genetics in Cancer MAGIC USA 16 / 18 8 (0) / 6 21 / 26 8 (0) / 3 
Mayo Clinic MAYO USA 138 / 243 138 (63) / 33 61 / 130 80 (0) / 11 
McGill University MCGILL Canada 30 / 50 24 (0) / 4 15 / 26 12 (0) / 1 
Modifier Study of Quantitative Effects on 
Disease 
MODSQUAD Czech Republic 67 / 132 107 (0) / 42 0 / 0 0 (0) / 0 
Memorial Sloan-Kettering Cancer 
Center 
MSKCC USA 137 / 311 201 (0) / 27 97 / 195 121 (0) / 23 
General Hospital Vienna MUV Austria 222 / 380 224 (184) / 66 77 / 187 123 (88) / 13 
Women’s College Research Institute NAROD Canada 100 / 125 46 (0) / 21 0 / 0 0 (0) / 0 
National Cancer Institute NCI USA 113 / 145 44 (0) / 12 59 / 74 21 (0) / 6 
National Israeli Cancer Control Center NICCC Israel 0 / 0 0 (0) / 0 108 / 162 61 (0) / 7 
N.N. Petrov Institute of Oncology NNPIO Russia 17 / 36 34 (0) / 15 0 / 0 0 (0) / 0 
Ontario Cancer Genetics Network OCGN Canada 139 / 170 74 (0) / 43 112 / 156 65 (0) / 21 
The Ohio State University 
Comprehensive Cancer Center 
OSUCCG USA 33 / 77 53 (0) / 9 28 / 52 33 (0) / 9 
Odense University Hospital OUH Denmark 225 / 304 141 (121) / 62 116 / 189 88 (53) / 15 
Università di Pisa PBCS Italy 35 / 57 45 (0) / 23 0 / 0 0 (0) / 0 
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CIMBA Study Name Abbreviation Study Location N Unaffected 
BRCA1 carriers:  
BC / OC 
N Affected BRCA1 
carriers: BC (with 
survival) / OC 
N Unaffected 
BRCA2 carriers: 
BC / OC 
N Affected BRCA2 
carriers: BC (with 
survival) / OC 
Sheba Medical Centre SMC Israel 156 / 222 107 (0) / 41 57 / 94 47 (0) / 10 
Swedish Breast Cancer Study SWE-BRCA Sweden 266 / 372 220 (37) / 114 31 / 46 23 (0) / 8 
The University of Chicago Center for 
Clinical Cancer Genetics and Global 
Health 
UCHICAGO USA 35 / 56 25 (0) / 4 12 / 33 25 (0) / 4 
University of California Los Angeles UCLA USA 0 / 0 0 (0) / 0 25 / 38 15 (0) / 2 
University of California San Francisco UCSF USA 59 / 75 44 (0) / 28 11 / 23 16 (0) / 4 
United Kingdom Familial Ovarian 
Cancer Registries 
UKGRFOCR UK 42 / 25 18 (0) / 35 13 / 6 4 (0) / 11 
University of Pennsylvania UPENN USA 172 / 344 242 (138) / 70 104 / 215 131 (62) / 20 
University of Texas M.D. Anderson 
Cancer Center 
UTMDACC USA 44 / 97 71 (0) / 18 0 / 0 0 (0) / 0 
Victorian Familial Cancer Trials Group VFCTG Australia 14 / 37 40 (0) / 17 0 / 0 0 (0) / 0 
Women’s Cancer Program WCP USA 158 / 154 55 (0) / 59 56 / 55 17 (0) / 18 
TOTAL   7,222 / 12,433 7,543 (1,706) / 2,332 3,766 / 7,305 4,138 (917) / 599 
 
Totals represent the number of subjects passing quality control criteria included in these analyses. BC = breast cancer, OC = ovarian cancer; number in parentheses is number with 
survival time data 
Page 8 of 8 
 
Supplementary Table S4.  Association between KRAS rs61764370 and Risk of 
ERBB2-positive and High Grade Breast Cancer in Hormone Replacement Therapy 
Users 
 
 TT TG GG N Cases MAF OR (95% CI) P-value 
HRT users              
ERBB2 status        
    Negative 1,213 240 13 1,466 0.0907   
    Positive 224 55 2 281 0.1050 1.13 (0.84-1.54) 0.42 
Grade        
    1 or 2 1,638 331 14 1,983 0.9052   
    3 461 107 9 577 0.1083 1.12 (0.96-1.49) 0.11 
Postmenopausal HRT users 
   
 
   
ERBB2 status        
    Negative 1,084 221 12 1,317 0.0930   
    Positive 190 50 2 242 0.1116 1.20 (0.87-1.65) 0.27 
Grade        
1 or 2 1,477 307 14 1,798 0.0932   
    3 414 100 8 522 0.1111 1.20 (0.95-1.51) 0.12 
 
Breast cancer analyses used BCAC data adjusted for study, age, and the first seven principal components.  
HRT, hormone replacement therapy; N, number; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval 
 
 
Supplementary Table S5.  Results of OCAC Analyses of Genotyped and Imputed Variants in a 100 kb Region on Either Side of KRAS
1000G Name Chromosomal Position (Build 37) Reference Allele
rs17327547 25258458 G
chr12:25258574:I 25258574 GA
rs142258134 25259157 C
chr12:25259356:D 25259356 T
chr12:25259581:D 25259581 T
chr12:25259628:D 25259628 T
chr12:25259676:I 25259676 AT
rs17386824 25259750 A
rs113123645 25260675 G
rs11047837 25261165 G
rs73081704 25262127 C
chr12:25262348:D 25262348 T
rs77156774 25263310 G
rs75700820 25263397 T
rs7134616 25263890 C
rs4963848 25263951 T
rs17387019 25264259 A
rs76474389 25265248 G
rs7297103 25265295 T
rs56009712 25265339 G
rs138327616 25265409 C
rs140262765 25265442 G
rs6487454 25265604 T
rs6487455 25265654 A
rs73081707 25265795 C
rs11047842 25265837 A
rs10842469 25266165 C
rs10842470 25266203 T
rs149734680 25266436 G
rs11047843 25266794 T
chr12:25266885:I 25266885 TG
rs11047845 25266983 A
chr12:25267104:I 25267104 CCTCA
rs74426171 25267557 T
rs10842471 25267940 A
rs11047846 25267999 T
chr12:25268475:I 25268475 CAAA
chr12:25268476:I 25268476 AAAG
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HIGHLIGHTS 
 A clinical genetic test for KRAS rs61764370 is marketed to US women at increased ovarian 
or breast cancer risk. 
 The genotype of KRAS rs61764370 has no clinical utility related to the prediction or 
management of ovarian or breast cancers. 
 The results of this study demonstrate the necessity of carefully conducted, large-scale 
studies to establish clinical validity for genetic tests. 
 
*7. Highlights (for review)
